CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 1 -  
CLINICAL STUDY PROTOCOL  
Protocol Title:  A Multicenter,  Open -label, Single -arm, Phase 2 Study to 
Evaluate Safety and Organ Uptake Quantitation Repeatability of 
124I-AT-01 using Positron Emission Tomography/ X-ray 
Computed Tomography (PET/CT) in Subjects with Systemic 
Amyloidosis  
Protocol Number:  AT01-001 
Amendment Number:  2.0 
Version Date:  08 March 2022  
Supersedes:  1.1 (Dated: 07 October 2021)  
Investigational Product : 124I-AT-01 
Study Phase:  2 
Study Acronym/Name:  N/A 
Brief Protocol Title:  An Open -label, Phase 2 Study to Evaluate Organ Level Uptake  
Quantitation Repeatability of 124I-AT-01 in Subjects with 
Systemic Amyloidosis  
Sponsor  Name and 
Address: Attralus, Inc.  
50 Francisco Street , Suite 450 
San Francisco, CA 94133 
Sponsor Contact /Medical 
Monitor: Gregory Bell, MD  
Chief Medical Officer  
Tel.: +1 415-435-6210 
Email: gbell@attralus.com  
IND Number:  132282  
EudraCT Number:  N/A 
CONFIDENTIAL  
This protocol contains confidential information about a product provided by Attralus, Inc. This information is 
provided for the exclusive use of the Investigators participating in this study. Any and all confidential 
information contained herein may not be disclosed to any other  person or party without the prior written 
consent of Attralus, Inc. Attralus, Inc. ™/® are trademarks of Attralus, Inc. All other brand names/product 
names are trademarks of their respective owners . 
CONTACT FOR MEDICAL EMERGENCIES:  
Gregory Bell, M.D. 1-415- 845-4304  
gbell@attralus.co m  

CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 2 - SPONSOR SIGNATORY 
 
Study Title:  A Multicenter,  Open -label, Single- arm, Phase 2 Study to Evaluate 
Safety and Organ Uptake Quantitation Repeatability of 124I-AT-01 
using Positron Emission Tomography/X-ray Computed 
Tomography (PET/CT) in Subjects with Systemic Amyloidosis  
Protocol Number:  AT01-001 
Amendment Number:  2.0 
Version Date:  08 March 2022 
Protocol A ccepted and A pproved by: 
Gregory Bell, MD Chief Medical Officer  
Attralus, Inc.  
329 Oyster Point Blvd, Third Floor 
South San Francisco, CA 94080 
 
  ________________________________________________ 
Signature  
  __________________________ 
Date  
 
  
DocuSign Envelope ID: BC4932CC-2F4A-4330-8536-3DB9F188D3A4
3/8/2022

CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 3 - PRINCIPAL INVESTIGATOR SIGNATORY  
 
Study Title:  A Multicenter,  Open -label, Single- arm, Phase 2 Study to Evaluate 
Safety and Organ Uptake Quantitation Repeatability of 124I-AT-01 
using Positron Emission Tomography/X-ray Computed 
Tomography (PET/CT) in Subjects with Systemic Amyloidosis  
Protocol Number:  AT01-001 
Amendment Number:  2.0 
Version Date:  08 March  2022 
 
I have read the protocol described above, concur that it contains all information necessary to conduct the study, and agree to abide by all provisions set forth therein. I agree to conduct this study in accordance with the International Council on Harmonisation Tripar tite Guideline on 
Good Clinical Practice (ICH E6 GCPs) and applicable local regulations. I will not initiate the study until I have obtained written approval by the appropriate Institutional Review Board (IRB) and have complied with all financial and administrative requirements of the governing body of the clinical institution and the Sponsor. I will obtain written informed consent from each study subject prior to performing any study specific procedures that are NOT my routine standard of care. I understan d that my signature on a case report form indicates that the data 
therein has been reviewed and accepted by me. I understand that this document and related information is subject to confidentiality terms found in my signed Confidentiality or Clinical Servi ces Agreement. I agree to protect the confidentiality of my patients when allowing the 
Sponsor of this clinical investigation, and/or relevant regulatory authorities and IRBs, direct access to my medical records for study subjects. 
 
 ________________________________________________ 
Signature  
 __________________________ 
Date  
 
  
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 4 - TABLE OF CONTENTS  
1.0 PROTOCOL SUMMARY  ..............................................................................................10 
1.1 Synopsis .................................................................................................................10 
1.2 Study Schema.........................................................................................................13 
1.3 Schedule of Activities ............................................................................................14 
2.0 INTRODUCTION ............................................................................................................16 
2.1 Study Rationale ......................................................................................................16 
2.2 Background ............................................................................................................16 
2.2.1 Systemic Amyloidosis ...........................................................................16 
2.2.2 Description of 124I-AT-01 .....................................................................17 
2.3 Benefit/Risk Assessment  .......................................................................................18 
2.3.1 Potential Benefits  ..................................................................................18 
2.3.2 Potential Risks .......................................................................................18 
2.3.3 Benefi t/Risk Conclusion  .......................................................................20 
3.0 OBJECTIVES AND ENDPOINTS  ................................................................................21 
4.0 STUDY DESIGN ..............................................................................................................22 4.1 Overall Desi gn .......................................................................................................22 
4.1.1 Screening Period ...................................................................................22 
4.1.2 Pre-Administration Period  ....................................................................22 
4.1.3 Administration Period  ...........................................................................22 
4.1.4 Follow-up Period ...................................................................................23 
4.1.5 Early Termination Visit  ........................................................................24 
4.2 Scientific Rationale for Study Design  ....................................................................24 
4.2.1 Choice of Population .............................................................................24 
4.2.2 Choice of Primary Endpoint and Analysis ............................................24 
4.2.3 Choice of Duration of Treatment and Follow-up ..................................25 
4.3 Justification for Dose(s) and Posology ..................................................................25 
4.4 End of Treatment Definition ..................................................................................25 
4.5 
 End of Study Definitions .......................................................................................25 
4.6 Subject Completion Definition  ..............................................................................26 
5.0 STUDY POPULATION ..................................................................................................27 5.1 Inclusion Criteria  ...................................................................................................27 
5.2 Exclus ion Criteria  ..................................................................................................28 
5.3 Lifestyle Considerations  ........................................................................................29 
5.4 Screen Failures  .......................................................................................................29 
5.5 Subject Replacement  ..............................................................................................29 
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 5 - 6.0 STUDY INTERVENTION(S) AND CONCOMITANT THERAPY  ..........................30 
6.1 Study Intervention(s)  .............................................................................................30 
6.2 Preparation/Handling/Storage/Accountability  .......................................................30 
6.3 Measures to Minimize Bias ...................................................................................31 
6.4 Study Intervention Compliance .............................................................................31 
6.5 Dose Modifications/Interruptions and Retreatment Criteria  ..................................31 
6.6 Access to Study Intervention After End of Study ..................................................31 
6.7 Treatment of Overdose ..........................................................................................31 
6.8 Concomitant Medications and Procedures  .............................................................32 
6.8.1 Allowed Concomitant Medications and Procedures .............................32 
6.8.2 Prohibited Concomitant Medications and Procedures ..........................32 
6.8.3 Rescue Medication or Supportive Therapy for Adve rse Events  ...........32 
7.0 DISCONTINUATION OF STUDY INTERVENTION AND/OR SUBJECT 
DISCONTINUATION OR WITHDRAWAL  ...............................................................33 
7.1 Discontinuation of Study Intervention ...................................................................33 
7.1.1 Specific Stopping Criteria  .....................................................................34 
7.2 Missed Visits ..........................................................................................................35 
7.3 Lost to Follow-up ...................................................................................................35 
8.0 STUDY ASSESSMENTS AND PROCEDURES  ..........................................................36 
8.1 124I-AT-01 Organ Uptake Assessments  .................................................................36 
8.1.1 Medical History and Demographics......................................................36 
8.1.2 Biomarkers  ............................................................................................36 
8.1.3 Administration of 124I-AT-01 ................................................................36 
8.1.4 124I-AT-01 PET/CT Imaging  .................................................................36 
8.2 Safety Assessments ................................................................................................36 8.2.1 Vital Signs, Body Weight, and Height ..................................................36 
8.2.2 Clinical Laboratory Testing  ..................................................................37 
8.2.3 Pregnancy Testing .................................................................................37 
8.2.4 Unscheduled Safety Visits ....................................................................37 
8.3 
 Adverse Events, Serious Adverse Events, and Other Safety Reporting ................37 8.3.1 Time Period and Frequency for Collecting AE and SAE 
Information  ............................................................................................38 
8.3.2 Method of Detect ing AEs and SAEs .....................................................38 
8.3.3 Follow-up of AEs and SAEs .................................................................38 
8.3.4 Regulatory Reporting Requirements for SAEs .....................................39 
8.3.5 Pregnancy ..............................................................................................40 
8.3.6 Death Events .........................................................................................40 
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 6 - 9.0 STATISTICAL CONSIDER ATIONS  ...........................................................................41 
9.1 Study Hypothesis ...................................................................................................41 
9.2 Definition of Enrollment ........................................................................................41 
9.3 Sample Size Determination  ....................................................................................41 
9.4 Analysis Sets ..........................................................................................................41 
9.5 Statistical Analyses  ................................................................................................41 
9.5.1 General Considerations  .........................................................................41 
9.5.2 Primary Endpoint(s) ..............................................................................42 
9.5.3 Secondary Endpoint(s) ..........................................................................42 
9.5.4 Safety Analysis  .....................................................................................43 
9.6 Interim Analyses  ....................................................................................................44 
10.0 APPENDICES WITH SUPPORTING DOCUMENTATION AND 
OPERATIONAL CONSIDERATIONS  ........................................................................45 
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ................46 
10.1.1 Regulatory and Ethical Considerations  .................................................46 
10.1.2 Financial Disclosure  ..............................................................................46 
10.1.3 Informed Consent  ..................................................................................47 
10.1.4 Data Protection  ......................................................................................47 
10.1.5 Data Quality Assurance .........................................................................48 
10.1.6 Source Documents ................................................................................48 
10.1.7 Study and Site Start and Closure ...........................................................49 
10.1.8 Publication Policy  .................................................................................50 
10.2 Appendix 2: Clinical Laboratory Tests ..................................................................51 
10.3 Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ...................................................................52 
10.3.1 Definition of AE  ....................................................................................52 
10.3.2 Definition of SAE  .................................................................................53 
10.3.3 Recording and Follow-Up of AE and/or SAE ......................................54 
10.3.4 Reporting of SAEs ................................................................................55 
10.4 Appendix 4: Contraceptive and Barrier Guidance .................................................56 
10.4.1
 Definitions  .............................................................................................56 
10.4.2 Contraception Guidance ........................................................................57 
10.4.3 Collection of Pregnancy Information ....................................................58 
10.5 Appendix 5: Protocol Amendment History ...........................................................59 
11.0 REFERENCES  .................................................................................................................60 
 
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 7 - LIST OF TABLES  
Table 1:  Protocol AT01-001: Risk Assessment .......................................................19 
Table 2:  Protocol AT01-001: Study Intervention ....................................................30 
Table 3:  Protocol AT01-001: Amendment History .................................................59 
 
 
LIST OF FIGURES  
Figure 1:  Protocol AT01-001: Schema ......................................................................13 
 
  
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 8 - LIST OF ABBREVIATIONS  AND ACRONYMS  
Term  Definition  
ADA  Anti-drug antibodies  
AE Adverse event  
AL Amyloid light chain  
ATTR  Amyloid trans thyretin  
ALECT2  Amyloid leukocyte cell -derived chemotaxin -2 
AUC 0-t Area under the whole blood  radioactivity -time curve from time 0 to the last quantifiable 
drug concentration  
BMI  Body mass index  
BNP  Brain natriuretic peptide  
BP Blood pressure  
CBC  Complete blood count  
CFR  Code of Federal Regulations  
CIOMS  Council for International Organizations of Medical Sciences  
CL Apparent systemic clearance  
Cmax Maximum observed whole blood  radioactivity  
CMR  Cardiac magnetic resonance  
CNR  Contrast to noise ratio  
COVID -19 Coronavirus -19 
CR Complete response  
CRF  Case report form  
CRO  Contract or Clinical Research Organization  
CT Computerized tomography  
CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
DBP  Diastolic blood pressure  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EDC  Electronic data collection  
EOS  End of study  
ET Early termination  
FSH Follicle stimulating hormone  
GCPs  Good clinical practices  
HIPPA  Health Insurance Portability and Accountability Act  
HR Heart rate  
HRT  Hormone replacement therapy  
IB Investigator’s  Brochure  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IND Investigational new drug  
iOSAT  Potassium iodide (KI) 130 mg  
IRB Institutional review board  
IRR Infusion -related reaction  
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 9 - IV Intravenous  
λz Terminal elimination rate constant  
LAR  Legally authorized representa tive 
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  Magnetic resonance imaging  
NOAEL  No-observed -adverse -effect level  
NSAIDs  Nonsteroidal anti -inflammatory drugs  
NT-proBNP  N-terminal prohormone of brain natriuretic peptide  
NYHA  New York Heart Association  
OTC  Over the counter  
PBS Phosphate -buffered saline  
PET Positron emission tomography  
PK Pharmacokinetics  
PT Preferred term 
RBC  Red blood cell  
ROI Region(s) of interest  
SAE  Serious adverse event 
SAP Serum amyloid P -component; statistical analysis plan  
SBP Systolic blood pressure  
scFc Single chain Fc  
SD Standard deviation  
SNR  Signal to noise ratio  
SoA Schedule of Activities  
SOC  System organ class  
SOP Standard operating procedure  
SPECT  Single -photon emission computerized tomography  
SpO 2 Peripheral blood oxygen saturation level  
SUSAR  Suspected unexpected serious adverse reaction  
SUV  Standardized uptake value  
t1/2 Apparent terminal elimination half -life 
TEAE  Treatment -emergent adverse event  
Tmax Time of maximum observed whole blood radioactivity  
TnI Troponin I 
UACR  Urine albumin creatinine ratio  
UPT  Urine pregnancy test  
UTARP  UT Amyloidosis Research Program  
VGPR  Very good partial response  
Vss Apparent volume of distribution at steady state  
WBC  White blood cell  
WOCBP  Women of child bearing potential  
  
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 10 - 1.0 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol Number:  AT01-001 Version : 1.0 For National Authority 
Use Only  
 IND Number: 132282  EudraCT Number: N/A 
Sponsor:  Attralus, Inc  
Investigational Product : 124I-AT-01 
Title of Study:  A Multicenter, Open -label, Single -arm, Phase 2 Study to Evaluate Safety and Organ Uptake 
Quantitation Repeatability of 124I-AT-01 using  Positron Emission Tomography/X- ray Computed Tomography 
(PET/CT) in Subjects with Systemic Amyloidosis  
Brief Title:  An Open -label, Phase 2 Study to Evaluate Organ Level Uptake Quantitation Repeatability of 
124I-AT-01 in Subjects with Systemic Amyloidosis  
Brief Study Rationale:  
There currently are no approved imaging agents that specifically detect and quantify amyloid deposits in patients . 
As a positron emission tomography (PET)/X- ray computed tomography (CT) imaging agent that binds many forms 
of human a nd murine amyloid, 124I-AT-01 may fulfill this unmet clinical need by enabling detection of amyloid in 
abdominothoracic organs or tissues of patients with systemic amyloidosis. Thus, this study has been designed to 
assess the repeatability of organ -specifi c quantitation of radiotracer uptake following PET/CT imaging of AT -01 in 
subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis.  This will help to 
determine whether 124I-AT-01 can be used to monitor disease progression and treatment response in patients with 
systemic amyloidosis.  
Type of Study and Development Phase:   
Human pharmacology, Phas e 2 Countries/Regions:  
United States  
Study Period: Approximately  nine (9)  months . 
Objectives  and Key Endpoints : 
Objectives  Key Endpoints  
Primary  
To evaluate the repeatability of organ -specific 
quantitation of radiotracer uptake following PET/CT imaging of 
124I-AT-01 in subjects with AL or ATTR 
systemic amyloidosis . • Repeatability coefficient (Bland -Altman plots) and 
intraclass correlation coefficient (ICC)  associated 
with the quantification of radioactivity associated with organ level 
124IAT01 uptake measurements.  
Secondary  
• To characterize the safety and tolerability of repeat 
doses of 124I-AT-01 administered by IV infusion or 
slow IV bolus.  
 • Incidence of treatment -emergent AEs1 from Day 1 
to EOS.  
• Change from Baseline in clinical laboratory values 
at Visits 2 and Safety Follow -up 1 (1-3 days  after 
the second administration of 124I-AT-01). 
• Change from Baseline in vital signs.  
• Change from Baseline in ADA.  
 
Design/ Methodology:   
This is a multi center, open -label, single arm study in subjects with AL  or ATTR systemic amyloidosis. 124I-AT-01 
is the only study intervention; neither reference therapy nor placebo will be administered.  
Number of Subject s Planned:  
Approximately 20 Gender:  
Male or female  Age:  
≥18 years of age  
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 11 - Protocol Number:  AT01-001 Version : 1.0 For National Authority 
Use Only  
 IND Number: 132282  EudraCT Number: N/A 
Sponsor:  Attralus, Inc  
Investigational Product : 124I-AT-01 
Title of Study:  A Multicenter, Open -label, Single -arm, Phase 2 Study to Evaluate Safety and Organ Uptake 
Quantitation Repeatability of 124I-AT-01 using  Positron Emission Tomography/X- ray Computed Tomography 
(PET/CT) in Subjects with Systemic Amyloidosis  
Diagnosis and Key Criteria for Eligibility:  
Eligible subjects will have:  
• Has a history of AL or ATTR systemic amyloidosis with at least one organ with clinically demonstrable 
amyloid involvement.  
• Able to undergo 2 PET/CT scans as part of the study, including ability to lie supine for up to 1 hour . 
Total Subject  Duration:  
Approximately 14 weeks.  Treatment  Duration :  
Approximately 6 weeks  
Investigational Product , Dose , and Route  of 
Administration:   
124I-AT-01, 1 mCi ±10% (≤2 mg AT -01) via IV infusion 
or slow IV bolus at 1 mL/5 seconds  Control , Dose , and Route  of Administration:  
N/A 
Organ Uptake Quantitation  Evaluation : 
The repeatability of organ -specific quantitation of radiotracer uptake will be assessed using  PET/CT imaging of 
124I-AT-01 in subjects with AL or ATTR systemic amyloidosis . 
The signal to noise ratio ( SNR ) and contrast to noise ratio ( CNR) will be plotted against standardized uptake value 
(SUV) based metrics. Repeatability will be assessed using Bland -Altman plots. Intraclass correlation coefficient 
(ICC) and its associated 95% confidence interval will be presented.  
Safety Evaluation : 
All AEs and SAEs will be recorded from the time of informed consent until the final EOS telephone follow -up 
(~Week 10). AEs will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5. All 
adverse events occurring during the study  will be recorded and classified based on Medical Dictionary for 
Regulatory Activities (MedDRA) terminology. The number and percentage of subjects experiencing TEAEs and 
SAEs will be tabulated for the safety population by system organ class (SOC) and prefe rred term (PT). TEAEs and 
SAEs will be tabulated by severity and relationship to study medication. Each subject will be counted only once within a SOC or a PT by using the AE with the highest severity or greatest relationship, respectively, within each category.  
TEAEs or SAEs leading to early discontinuation will be summarized as described above.  
Listings for all reported adverse events, including SAEs, will be provided. In addition, separate listing for SAEs, AEs leading to premature withdrawal from the s tudy, and all deaths will be generated.  
Vital signs will include blood pressure (mmHg) and heart rate (beats per minute). Vital signs will be summarized at 
Baseline and for each study visit when vital signs were obtained. Changes from Baseline in vital sig n 
measurements will also be summarized. Baseline is defined as the last vital signs obtained prior to the initiation of study drug. 
CONFIDENTIAL  Protocol AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 12 - Protocol Number:  AT01-001 Version : 1.0 For National Authority 
Use Only  
 IND Number: 132282  EudraCT Number: N/A 
Sponsor:  Attralus, Inc  
Investigational Product : 124I-AT-01 
Title of Study:  A Multicenter, Open -label, Single -arm, Phase 2 Study to Evaluate Safety and Organ Uptake 
Quantitation Repeatability of 124I-AT-01 using  Positron Emission Tomography/X- ray Computed Tomography 
(PET/CT) in Subjects with Systemic Amyloidosis  
Statistical Considerations : 
This is an open -label, single arm study. In general, for continuous variables, the mean, standa rd deviation (SD), 
median, and range will be presented. Categorical variables will be summarized by frequency counts and 
percentages.  
Subject disposition will be summarized for all subjects who signed the ICF and will include the number of subjects who rec eived study treatment and the number and percentage of subjects who completed or prematurely 
discontinued the study, classified by reasons for premature discontinuation . 
Description of Data Monitoring:  
Study conduct and subject safety will be monitored on an ongoing basis by the study Sponsor.  
Version Date : 08 March  2022  
CONFIDENTIAL   Protocol AT0 1-001, Version 2.0 
Attralus, Inc.   124I-AT-01 
 - 13 - 1.2 Study Schema  
Figure 1: Protocol AT01-001: Schema  
  
Abbreviations: CT = computerized tomography; IV = intravenous; PET = positron emission tomography; SoA = schedule of activiti es. 
a. Begin oral KI for 3 days, beginning >30 minutes and <24 hr prior to dosing.  
b. 124I-AT-01 will be administered by IV infusion over 2- 5 minutes ( subjects enrolled under protocol Version 1.1) or slow IV bolus at 1 mL/5 seconds 
(subjects enrolled under protocol Version  2.0). For all subjects, 124I-AT-01 will be administered by the same route (IV infusi on over 2- 5 minutes or 
slow IV bolus at 1 mL/5 seconds) at the Week 6 visit as on the Day 1 visit . 
c. Subjects will be discontinued if amyloid deposits are not identified in the Day 1 PET/CT scan in at least one of the followin g organs: heart, liver, spleen 
or kidne y. 
d.  Record concomitant medications and conduct biomarker/safety assessments per SoA.  
e. Safety follow -ups will be done via telephone call for all subjects.   

CONFIDENTIAL   Protocol AT0 1-001, Version 2.0 
Attralus, Inc.   124I-AT-01 
 - 14 - 1.3 Schedule of Activities  
Visit  Screen ing Visit 1/ 
Day 1 Visit 2/ 
Week 6 Safety  
Follow -up 1 j Safety   
Follow -up 2 
(EOS ) j Early 
Termination  
(ET)  k,l 
Window  Day –30 
to 
Day 1 ± 0 days  Week 6 to Week 8  1-3 Days   
After Visit 2  28 (± 3) Days  
After Visit 2  <7 days  
from ET 
Decision  
Timing of Activity(ies)   Prior to  
124I-AT-01 124I-AT-01 
and Scan  Prior to  
124I-AT-01 124I-AT-01 
and Scan     
Assessment/Procedures          
Informed Consent  a X        
Medical history and Demographics  X        
Inclusion  and E xclusion criteria  X        
Concomitant Medications  X X X X X X X X 
Oral Potassium Iodide (KI ) b  X  X     
124I-AT-01 Administration  c   X  X    
Biomarker and Safety Assessments          
Vital Signs  (HR and BP)  d   X X X X    
Body Weight   X  X     
Height   X       
Pregnancy Test (WOCBP)  e,f X   X     
PET/CT Scan    X  X    
Adverse events  g X X X X X X X X 
Laboratory  h,i X   X  X   
Biomarkers  h,i X   X     
Urine UACR (AL subjects  only)  i X   X     
Serum ADA  i X   X   X X 
CONFIDENTIAL   Protocol AT0 1-001, Version 2.0 
Attralus, Inc.   124I-AT-01 
 - 15 - Abbreviations: ADA = anti -drug antibodies; AL = amyloid light chain amyloidosis; BP = blood pressure; CBC = complete blood count; EOS = end of 
study; ET = early termination; HR = heart rate; NT -proBNP = N -terminal prohormone of brain natriuretic peptide; U ACR = urine albumin -to-
creatinine ratio; WOCBP = women of childbearing potential.  
a. Informed consent, as described in Section 10.1.3. 
b. KI is self -administered by the subject daily for 3 days , beginning > 30 minutes and <24 hr prior to dosing, as described in Section 4.1.2. 
c. 124I-AT-01 will be administered by IV infusion over 2- 5 minutes  (protocol Version 1.1)  or slow IV bolus at 1 mL/5 seconds  (protocol 
Version 2.0) , as described  in Section 4.1.3. For all subjects, 124I-AT-01 will be administered by the same route (IV infusion over 2 -5 minutes 
or slow IV bolus at 1 mL/5 seconds) at the Week 6 visit as on the Day 1 visit.   
d. Subjects must r emain semi -recumbent for at least 5 minutes prior to blood pressure measurement s. Blood pressure and heart rate will be 
measured within an hour prior to dosing and 5 -10 minutes after administration of 124I-AT-01. 
e. Serum  pregnancy test, as indicated in Section 10.2, will be obtained in all women of childbearing potential.   
f. Serum pregnancy and all other laboratory samples must be drawn within 7 days prior to administration of  124I-AT-01 in all WOCBP . The 
results o f the pregnancy test must be available and be negative prior to 124I-AT-01 administration in all WOCBP.  
g. Adverse events will be monitored from Screening through the EOS Visit. For Safety Follow -up 1 and 2, adverse events and concomitant 
medications can be obtained by phone call.  
h. Clinical laboratory tests and biomarker analysis, as described in Section 10.2 . Baseline sample will be collected within 30 days prior to the 
first administration of 124I-AT-01; second sample within 7 days prior to the second administration of 124I-AT-01; third sample at Safety 
Follow -up 1 after the second administration of 124I-AT-01. 
i. Urine and blood may be collected locally by visiting nurse/phlebotomist.  An additional serum ADA sample will be obtained at Screening for 
subjects who provided consent for the extra ADA sample . 
j. Safety follow -ups for concomitant medications and adverse events will be done via telephone call for all subjects. Both Safety Follow -up 1 
and Safety  Follow -up 2 activities will be conducted for subjects who discontinue for IRR s at either the first or second administration of 
124I-AT-01.  
k. Blood draw for ADA should be obtained if ET is ≥4 weeks after first administration of 124I-AT-01.  
l. Early Termination activities do not apply to subjects discontinued for IRRs. Please follow Safety Follow -up 1 and Safety Follow- up 2 
activities for subjects experiencing IRR with either the first or second administration of 124I-AT-01. 
 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 16 - 2.0 INTRODUCTION  
124I-AT-01 is an amyloid- reactive synthetic peptide (p5+14 or APi1832) radiolabeled with 
iodine-124. T here currently are no approved imaging agents that specifically detect and quantify 
amyloid deposits in patients with systemic amyloidosis. A s a positron emission tomography 
(PET)/X-ray computed tomography ( CT) imaging agent that binds many forms of human and 
murine amyloid, it may fulfill this unmet clinical need by enabling detection of amyloid in 
abdominothoracic organs or tissues of patient s with systemic amyloidosis.  
2.1 Study Rationale  
Systemic amyloidosis is an incurable disease, and  about 20% of patients with cardiac or 
advanced kidney involvement experience early deaths (<1 year).  Recent progress in the 
treatment of AL amyloidosis with proteasome inhibitors, chemotherapies, and immunotherapies 
that target plasma cells has greatly improved patient prognosis; however, median survival 
remains low at approximately five years ( Milani 2018; Palladini 2020). Earlier quantitative 
detection of amyloid in abdominothoracic organs or tissues and assessment of response to treatment may improve the prognosis of these patients. However, t here currently are no approved 
imaging agents that specifically detect and quantify amyloid deposits in patients. 
As a PET/ X-ray CT  imaging agent that binds many forms of human and murine amyloid, 
124I-AT-01 may fulfill this unmet clinical need by enabling detection of amyloid in 
abdominothoracic organs or tissues of patients with systemic amyloidosis. Thus, this study has 
been designed to assess the repeatability of organ -specific quantitation of radiotracer uptake 
following PET/CT imaging of AT-01 in subje cts with amyloid light chain ( AL) or amyloid 
transthyretin  (ATTR ) systemic amyloidosis . This will help to determine whether AT -01 can be 
used to monitor disease progression and treatment response  in patients with systemic 
amyloidosis. 
2.2 Background 
2.2.1 Systemic A myloidosis  
Systemic amyloidosis is a rare protein misfolding and deposition disorder that results in tissue 
amyloid deposits and progressive organ failure. The amyloid deposits are composed of highly organized proteinaceous (amyloid) fibrils in association with proteoglycans (hypersulfated proteoglycans) and serum derived proteins, serum amyloid P, apolipoprotein E, and apolipoprotein A- IV (Muchtar 20 21). Amyloid is insoluble and resistant to degradation. The 
resistance to catabolism results in progressive tissue amyloid accumulation and organ dysfunction.  
Amyloidosis can be acquired or hereditary and can affect various organs, including the liver, 
spleen, heart, kidneys, peripheral and autonomic nervous systems, gastrointestinal tract, lungs and pleura, skin, and soft tissues. Symptoms are usually nonspecific and slowly progressive, resulting in delays in diagnosis. Approximately 37 different prote ins have been identified as 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 17 - amyloidogenic; at least 17 of them can cause systemic disease, in which the amyloidogenic 
protein is produced in one site (e.g., bone marrow, liver) and is deposited at distant site(s) (e.g. , 
heart, kidneys) ( Wechalekar 2016).  
The most common forms in the United States (US) are derived from immunoglobulin light chains (AL -associated amyloidosis), wild type or mutant transthyretin (wtATTR - and ATTR -
associated amyloid, respectively), leukocyte chemotactic factor 2 (ALECT2), or seru m amyloid 
protein A (AA). The incidence of visceral amyloidosis is estimated to be ~8 patients per 
1 million persons per year, with ~4,500 new cases diagnosed every year in the US ( Wechalekar 
2016).  
Current Imaging Diagnostics 
Currently, there are no approved methods to document the extent of whole-body amyloid 
deposition or its response to treatment. Thus, there is a critical need to develop a method for objective, quantitative visualization of a patient’s amyloid burden.  
Routine anatomic imaging techniques (i.e., CT, magnetic resonance imaging ( MRI ), ultrasound) 
are not “amyloid- specific”. Furthermore, organ- specific amyloid deposits are rarely visualized 
with current approved nuclear medicine agents. Although European investigators have imaged 
cardiac a myloid distribution  in patients with ATTR amyloidosis using planar gamma 
scintigraphy or single-photon emission computerized tomography ( SPECT ) imaging with 
123I-
labeled serum amyloid P-component (SAP) ( Hazenberg 2007 ), 99mTc-aprotinin or 99mTc- 3,3-
diphosphono-1,2 propanodicarboxyli c acid (DPD) (Rapezzi 2011), these agents are not approved 
in the US, nor do they detect amyloid in all affected organ sites. T he FDA- approved Aβ amyloid 
imaging agents, 18F-Florbetapir (Amyvid), 18F-Flutemetamol (Vizamyl), and 18F-Florbetaben 
(Neuraceq), are only approved for use in very specific populations of suspected Alzheimer’s disease patients and have not been show n to be effective at imaging systemic amyloid in organs 
other than the heart in some patients; therefore, they are not suitable for providing non-invasive detection of whole- body amyloid load (Dorbala 2014).  
2.2.2 Description of 
124I-AT-01 
124I-AT-01 is an amyloid- reactive synthetic peptide (p5+14 or APi1832) radiolabeled with 124I 
under development for use as a PET/CT imaging agent for the detection of amyloid in abdominothoracic organs or tissues of patients with systemic amyloid dis ease.  AT-01 (p5+14 or 
APi1832) is  a synthetic, all natural, 45 amino acid peptide (MW = 4763.46 Da ) with a net +12 
positive charge that has been shown to specifically bind to amyloid in vitro  and in vivo  (Wall 
2015).  
Clinical experience with 
124I-AT-01 is derived from Study AMY1001 (NCT: [STUDY_ID_REMOVED]), a 
single- center, open- label, exploratory, Phase 1/2  PET/CT imaging study to detect amyloidosis in  
57 subjects, 50 of which had systemic amyloidosis, two (2) of which were asymptomatic ATTR 
carriers, and five  (5) of which were healthy volunteers . The primary outcome measure wa s 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 18 - localization of  AT-01 using PET/CT imag ing following a single dose via intravenous (IV) 
infusion. Overall, 124I-AT-01 was well tolerated, with no deaths or drug- related serious adverse 
events. The gender -averaged, whole-body, effective dose for 124I-AT-01 in the first three subjects 
was estimated to be 0.24  ± 0.02 mSv/MBq (8.7 mSv/mCi). The whole blood radioactivity half-
life was 21.9 hours. 124I-AT-01 was detected in one or more organs in >90% of patients with 
systemic amyloidosis, including detection in the heart, kidney, liver, and spleen. 124I-AT-01 was 
detected in the liver and kidney in one (1) of five (5) healthy volunteers (both organs were 
identified in the same subject) .  
A detailed description of the chemistry , mechanism of action, and nonclinical pharmacology of 
124I-AT-01 is provided in the Investigator’s Brochure (IB).  
2.3 Benefit/Risk Assessment  
2.3.1 Potential Benefits  
Based on the initial study of 124I-AT-01 in patients with known systemic amyloidosis, 124I-AT-01 
has been shown to detect amyloid in the heart, kidney, liver, spleen, and pancreas but does not bind to these organs in healthy volunteers , indicating that 
124I-AT-01 may enable a 
comprehensive assessment of the extent and severity of amyloid deposition in patients with systemic amyloidosis. This information may benefit patients by supporting a diagnosis, providing information on am yloid organ deposition and severity/exten t of disease, and enabl ing 
monitoring of disease progression and response to therapies.  
2.3.2 Potential Risks  
Clinically significant potential risks  and their mitigation strategies  are summarized in  Table 1 . As 
with all imaging studies involving radiopharmaceuticals, the greatest risks to subject s in this 
study are associated with reactions  to the radiotracer and the radiation dose associated with the 
injected radionuclide and external x- rays associated with the CT component of the PET/CT scan.  
These risks are described in Sections 2.3.2.1 and 2.3.2.2. 
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 19 - Table 1: Protocol AT01-001: Risk Assessment  
Potential Risk  Rationale for Risk  Risk Mitigation Strategy  
Study Intervention(s)  
Infusion -related 
reactions  As with all protein /peptide  
infusions , there is a potential for  an 
infusion -related  reaction (IRR) in 
subject s administered  124I-AT-01 
(Doessegger 2015).  Subjects will be monitored during and following the 
administration of 124I-AT-01 and instructed to 
report any symptoms indicative of an IRR without 
delay  (Section  7.1.1.1 ). 
Immunogenicity  As with all therapeutic proteins, 
there is a potential for an immune 
response in subject s administered 
124I-AT-01. Subject s will be monitored during and following the 
administration of 124I-AT-01and instructed to report 
any symptoms indicative of an immune  response 
without delay.  
Radiation exposure  124I-AT-01 contains radioactive 
iodine .  Subject s exposed to 124I-AT-01 will be pretreated 
with nonradioactive elemental iodine (127I), 
administered as potassium iodide (KI) at 
recommended doses prior to and for 3 days after 
dosing ( Section 2.3.2.1). 
Subjects must agree to prevent pregnancy during the study and for at least 90 days afterwards 
(Section 5.1). 
Study Procedures  
Exposure to 
SARS -CoV -2 virus  International guidelines (e.g., FDA 
Guidance on Conduct of Clinical 
Trials of Medical Products During 
the COVID- 19 Public Health 
Emergency) on the conduct of 
clinical trials during the COVID -19 pandemic.  Section 2.3.2. 2. 
Abbreviations: CT = computed tomography ; ECG = electrocardiogram ; FDA = United States Food and Drug 
Administration; PET = positron emission tomog raphy; SpO 2 = peripheral blood oxygen saturation. 
 
2.3.2.1 Risks Associated with Radiation Exposure  
124I is one of several radioactive isotopes of iodine commonly used in human research and 
medical care  with a radioactive half -life of 4.2 days.  The clinically important risk of exposure to 
124I derives from the potential sequestration of iodine in the thyroid gland and the concentration 
of radiation exposure in that gland. Subjects exposed to 124I as 124I-AT-01 w ill be treated with 
three  daily dos es of nonradioactive elemental iodine (127I), administered as potassium iodide 
(KI), at recommended doses beginning >30 minutes and within 24 hours prior to dosing. No 
other clinically important untoward effects of this well- characterized iodine isotope are expected 
at the doses planned in this study.  
From Study AMY1001, the gender-averaged mean whole- body effective rad iation  dose 
associated with 124I-AT-01 was 0.24 ± 0.02 mSv/MBq . Therefore, the 1 mCi dose used for each 
dose in this study will result in an estimated whole-body effective dose of ~8.7 mSv associated 
with the radiotracer. The whole blood radioactivity half-life was 21.9 hours. Whole blood 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 20 - radioactivity levels were <100 Bq/mL  at 48 hrs following a single 1 mCi dose of 124I-AT-01 
(Wall 2021).  
Subjects will also be exposed to radiation from the PET/ CT imaging. To reduce radiation dose 
from the PET/CT protocol, image acquisition w ill use  a low -dose CT for attenuation correction.  
Women of childbearing potential must also agree to remain as abstinent (refr ain from 
heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per 
year during the treatment period and for at least 90 days after the last dose of study intervention. Men with female partners of childbearing potential must also agree to remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 30 days plus 90 days (a spermatogenesis cycle) after the last d ose of study intervention. Men must also agree to refrain from donating sperm 
during this same time period . Additi onal details are provided in Section 5.1 . 
2.3.2.2 Risks Associated with Exposure to the Virus SARS -CoV -2 
In consideration of the Coronavirus disease (COVID-19) pandemic caused by the virus SARSCoV- 2 and the impact it may have on clinical trials, COVID -19 related risks to subject s 
are carefully considered and will be documented on an ongoing basis. Measures that prioritize trial subject  safety and data integrity have been developed in consideration of local guidelines. 
To minimize risk of exposure associated with trial participation, the Schedule of Activities (SoA) 
(Section 1.3 ) has been optimized to allow for an adequate follow- up and assessment of the safety 
of 
124I-AT-01, without unnecessarily increasing subject exposure.  
As the pandemic situation evolves, the Sponsor will reassess risks, which will be documented a s 
part of the Sponsor's trial master file. If  escalation of the pandemic during this trial and local 
circumstances lead to a local change in risk assessment, additional measures may be implemented. In this case, an Investigator- driven risk assessment will be conducted and 
documented in the Investigator’s site master file and communicated to the Sponsor. 
2.3.3 Benefit/Risk Conclusion  
The potential benefits of having a comprehensive assessment of the extent of amyloid deposits in 
subject s with systemic amyloidosis have been considered against the risks associated with (i) 
124I-AT-01, (ii) the study procedures, (iii) the method of administration, and (iv) the COVID-19 
pandemic. Subject s in this study will be closely monitored for potential risks. Eligibility criteria  
excludes subject s with higher risk, including those with significant co -morbidity such as Eastern 
Cooperative Oncology Group ( ECOG) score of 3 or greater, New York Heart Association 
(NYHA) Class IV heart failure, or other ongoing serious illness. 
For patients with systemic amyloidosis, there is a substantial medical need for  amyloid- specific 
imaging diagnostics. Therefore, the Sponsor considers that the value of the information to be gained outweighs the risks associated with participating in this stud y.   
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 21 - 3.0 OBJECTIVES AND ENDPOINTS  
Objective  Endpoint  
Primary  
• To evaluate the repeatability of organ -specific 
quantitation of radiotracer uptake following 
PET/CT imaging of 124I-AT-01 in subjects with 
AL or ATTR systemic amyloidosis . • Repeatability coefficient (Bland -Altman plots) and 
ICC associated with the quantification of radioactivity associated with organ level 
124I-AT-01 uptake measurements . 
Secondary  
• To characterize the safety and tolerability of repeat 
doses of 124I-AT-01 administered by IV infusion or 
slow IV bolus .  
 • Incidence of treatment -emergent AEs1 from Day 1 
to EOS . 
• Change  from Baseline  in clinical laboratory 
values2 at Visits 2 and Safety Follow -up 1 (1-3 
days after the second  administration of 
124I-AT-01). 
• Change from Baseline in vital signs.  
• Change from Baseline in ADA . 
Abbreviations: ADA = anti -drug antibodies;  AEs = adverse events; AL = amyloid light chain ; ATTR = a myloid 
transthyretin ; CT = computerized tomography ; EOS = end of study; ICC = intraclass correlation coefficient ; 
IV = intravenous ; PET = p ositron emission tomography . 
1. Adverse events will be graded using National Cancer Institute Common Terminology Criteria for Adverse 
Events  (CTCAE ) version  5. 
2. Clinical laboratory tests are described in Section 10.2  and include hematology  and serum chemistry.  
 
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 22 - 4.0 STUDY DESIGN 
4.1 Overall Design 
This is a multi center, open- label, single  arm study in subject s with AL or ATTR  systemic 
amyloidosis. 124I-AT-01 is the only study intervention; neither reference therapy nor placebo will 
be administered.  
This study consists of a screening period of up to 30 days; two,  one-day treatment period s (Day  1 
and Week 6); a safety  follow -up 1- 3 days  after the second  administration of 124I-AT-01, and a 
final safety follow -up 28 ±  3 days after the second  administration of 124I-AT-01. Thus, the total 
subject duration is approximately  14 weeks. 
Adverse events will be monitored and recorded from S creening through the final s afety follow-
up/EOS . The schedule for all screening, treatment, and follow -up period activities is  provided in 
the SoA ( Section  1.3). 
4.1.1 Screening Period  
The screening period is up to 30 days.  Eligibility criteria ( Section 5.0) will be con firmed  and 
informed consent , as specified in Section 10.1.3, will be obtained. Blood and urine tests as 
outlined in the SoA ( Section  1.3) will be obtained during the screening period.  
In WOCBP, s erum pregnancy and all other laboratory samples must be drawn within 7 days 
prior to 124I-AT-01 administration. The results of the pregnancy test must be available and be 
negative prior to 124I-AT-01 administration in all WOCBP. 
4.1.2 Pre-Administration  Period  
Subjects will begin therapy with KI 130 mg (e.g., iOSAT, Potassium Iodide Oral Solution USP, 
65 mg/mL ) orally once every day for 3 days beginning at least 30 minutes and within 24 hours 
prior to dosing with 124I-AT-01 on the Day 1 and Week 6 visits to block radioactive iodine 
uptake in the thyroid gland.  
4.1.3 Administration Period  
Administration of 124I-AT-01 and the associated study procedures occur at the  Day 1  and Week 6 
(+ 2 week) visits . Administration of 124I-AT-01 and the associated study procedures are  described 
in Section  4.1.3.1.  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 23 - 4.1.3.1 Administration of Study Intervention(s) and Associated Procedures  
Day 1 and Week 6 (+ 2 week) Visits  
The schedule for administration of 124I-AT-01 is provided in the SoA ( Section  1.3). 
Administration of 124I-AT-01 occurs at the  Day 1  and Week 6 to Week 8 visits , as follows:  
Prior to Administration of 124I-AT-01  
1) Clinical laboratory tests and biomarker analysis  (including serum pregnancy test in WOCBP) 
will be obtained  within 7 days prior to the second administration of 124I-AT-01, as described 
in the SoA ( Section  1.3). Th e results of the pregnancy test must be available and be negative 
prior to 124I-AT-01 administration in all WOCBP.  
2) Instruct subject to take oral KI daily for 3 days, as described in Section 4.1.2. 
3) Record  concomitant medicatio ns and monitor and record AEs throughout the study visit. 
Administration of 124I-AT-01 
4) Subjects enrolled under protocol Version 2.0 will receive a single dose of 1  mCi (± 10%) 
124I-AT-01 by slow IV  bolus at a rate of 1 mL/ 5 seconds. During 124I-AT-01 administration, 
monitor subjects for infusion- related reactions  (IRRs) , as described in Section  7.1.1. For all 
subjects, 124I-AT-01 will be administered by the same route (IV infusion over 2-5 minutes or 
slow IV bolus at 1 mL/5 seconds) at the Week 6 visit as on the Day 1 visit. 
After Completion  of Administration of 124I-AT-01 
5) Blood pressure and heart rate will be measured 5- 10 minutes after administration of 
124I-AT-01. 
6) Subjects will undergo a PET/CT scan 5 hours (± 30 minutes) after the start of administration  
of 124I-AT-01 to quantify 124I-AT-01 uptake in organs. 124I-AT-01 whole-body scans will be 
acquired by study-designated PET/CT scanners , as described in Section 8.1.4. 
Subjects will be discontinued if amyloid deposits are not identified in the Day 1 PET/CT 
scan in at least one of the following organs: heart, liver, spleen or kidney (i.e., they will not 
receive a second administration  of 124I-AT-01 or under go a second scan ) and  will undergo 
early termination (ET) activities , as provided in the SoA ( Section  1.3) and as described in 
Section  4.1.5. 
7) Any adverse events will be recorded; patient can be discharged after completing the scan and deemed stable by study staff. 
4.1.4 Follow- up Period  
As shown in the SoA ( Section  1.3), the follow-up period is 28 +/ - 3 days after the second  
administration of 
124I-AT-01. It consists of the following: 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 24 - • Safety Follow -up 1: a safety follow-up phone call 1-3 days after the second  
administration  of 124I-AT-01 and a safety laboratory draw 1-3 days after the second  
administration  of 124I-AT-01; and  
• Safety Follow -up 2: a final safety follow -up phone call 28 ± 3 days after the second  
administration  of 124IAT-01 for collection of AEs and concomitant medication, and a 
blood draw 28 ± 3 days after the second administration  of 124I-AT-01 for  anti-drug 
antibodies (ADA).   
Blood draws for laboratory and ADA will be collected locally by visiting nurse/phlebotomist . 
Both Safety Follow-up 1 and Safety Follow-up 2 activities will be conducted for subjects who 
discontinue for IRR s, as described in  Section 7.1.1.1, at either the first or second administration 
of 124I-AT-01. 
4.1.5 Early Termination Visit  
Subjects that are w ithdrawn or discontinued per the criteria provided in Section 7.1 will undergo 
the ET activities provided in the SoA ( Section  1.3) within  7 days from the early termination 
decision. Blood draw for ADA should be obtained if ET is ≥4 weeks after  the first administration 
of 124I-AT-01 of 124I-AT-01 and will be collected locally by visiting nurse/phlebotomist.  
ET activities do not apply to subjects discontinued for IRRs. Safety Follow -up 1 and Safety 
Follow-up 2 activities ( Section 4.1.4 ) will be con ducted for subjects who discontinue for IRRs at 
either the first or second administration of 124I-AT-01.  
4.2 Scientific Rationale for Study Design  
This is a multi center , open- label, single  arm study in subject s with systemic amyloidosis  to 
evaluate the repeatability of organ- specific quantitation of radiotracer uptake following PET/CT 
imaging of 124I-AT-01 in subjects with AL or ATTR systemic amyloidosis.  
4.2.1 Choice of Population 
124I-AT-01 is designed to selectively bind to amyloid; therefore,  the objectives of this study can 
only be met by including subjects with documented systemic amyloidosis and known visceral organ amyloid deposits. Subject s with AL or ATTR systemic amyloidosis were selected for this 
study because these are the most common forms of systemic amyloidosis at the study site s. 
4.2.2 Choice of Primary Endpoint and Analysis  
The primary endpoint is t o evaluate the repeatability of organ- specific quantitation of radiotracer 
uptake using PET/CT imaging of 
124I-AT-01 in subjects with AL or ATTR systemic amyloidosis. 
To evaluate organ uptake of 124I-AT-01 using PET/CT as a quantitative imaging biomarker, 
quantitative readings must be repeatable and reproducible ( Meikle 2021 ).  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 25 - 4.2.3 Choice of Duration of Treatment and Follow -up 
124I-AT-01 is eliminated by radioactive decay (half-life ~ 4.2 days), cell-mediated protein 
clearance, and catabolism. Ten radioactive half- lives will  assure complete clearance of 
radioactivity after the first PET/CT imaging visit and before the second PET/CT imaging visit. 
Ten half- lives is ~ 6 weeks.  Thus, the two doses of 124I-AT-01 will be separated by  at least 6 
weeks. A final safety follow -up 28 days after the second  dose of 124I-AT-01 represents more than 
five half-lives, a routinely recommended post- treatment safety assessment period ( CIOMS 
2005). 
4.3 Justification for Dose (s) and Posology 
In the AMY1001 trial, doses of 0.3, 1, and 2 mCi of 124I-AT-01 were evaluated . All but the first 
five subjects in the AMY1001 study received  a 2 mCi dose of 124I-AT-01. However, review of 
the experience in the AMY1001 study indicated that the 1mCi dose of 124I-AT-01provides 
sufficient exposure to characterize amyloid deposits. Th e 1mC i dose is being used in a study 
conducted under a separate IND at Brigham and Women’s Hospital and will be used in this 
study. This dose is associated with  ≤2 mg of p5+14 peptide (AT -01). The nonclinical safety of 
AT-01 was evaluated in a single IV  dose toxicity study in Sprague Dawley rats. A maximum 
tolerated dose was not determined , and the no- observed -adverse- effect -level (NOAEL) was 
considered to be at least 17.6 mg/kg (105.8 mg/m2) for a single IV  dose administration in rats. 
This dose is approximately 100-fold greater than the maximum 2 mg dose (~0.03 mg/kg) 
intended for administ ration  to patients. Additional details are provided in the  IB. 
4.4 End of Treatment Definition  
Subject s may withdraw from th is study at any time and for any reason and shall not be subject to 
prejudice to further medical care by the Investigator or study site. Reasons for end of treatment and/or ET are provided in Section 7.0. 
4.5 End of  Study Definition s 
If, during the study, it becomes evident to the Sponsor that the study should be stopped prematurely, the study will be terminated and appropriate notification will be given to the Investigator(s) and IRB (s), as applicable. The Sponsor, or designee, will instruct the 
Investigators to stop dispensing study materials/treatment and to arrange for study closeout at each site.  
The end of the study is defined as whichever of the following comes first: 
• The last safety follow-up of the last enrolled subject ; or  
• The Sponsor’s decision to terminate the study. 
The Sponsor, or designee, will notify the Investigator when to contact the IRB to inform them 
that the study is complete . 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 26 - 4.6 Subject  Completion  Definition  
Subjects have  completed the study when they have received  both  administrations of 124I-AT-01 
and both PET/CT scans  and have completed the EOS activities, including the final safety follow-
up telephone call and blood draw. Subjects who require further follow-up for an a dverse event 
(AE) will be followed according to Section 8.3. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 27 - 5.0 STUDY POPULATION 
Subject s will be enrolled and will receive study treatment only if they meet all inclusion criteria 
(Section 5.1 ) and none of the exclusion criteria ( Section 5.2 ). 
5.1 Inclusion Criteria  
Subjects are eligible to be included in the study only if all  the following criteria apply : 
1) Understands the study procedures and is c apable of giving signed informed consent, as 
described in Appendix 1, which includes compliance with the requirements and restrictions 
listed in the informed consent form (ICF) and in this protocol. 
2) Male or female ≥18 years of age. 
3) Has a history of AL or ATTR systemic amyloidosis with at least one organ with clinically 
demonstrable amyloid involvement defined by: 
a) For AL  systemic amyloidosis:  
i) Positive tissue (e.g., fat-pad, gastrointestinal  tract, etc .) bio psy for AL amyloid, and 
ii) Achieved a hematologic very good partial response (VGPR) or complete response 
(CR) based on their most recent assessment and within 12 months of screening, and 
iii) At least one of the following: (1) Cardiac, renal, or liver biopsy positive for amyloid, or 
(2) NT-proBNP >650 pg/mL, or 
(3) Left ventricle septal wall thickness >12 mm by echocardiogram or cardiac 
magnetic resonance (CMR) , or 
(4) 24-hour urine protein >500 mg, or  
(5) Urine albumin -to-creatinine ratio (UACR) >300 mg/g. 
b) For ATTR (wild type or variant) systemic amyloidosis: i) Positive cardiac biopsy for ATTR amyloid, or 
ii) At least two of the following:  (1) Positive extracardiac tissue (e.g., fat -pad, GI tract, etc.) biopsy for ATTR amyloid 
or positive transthyretin gene mutation associated with amyloid (obtained at any 
time), or  
(2) Left ventricle septal wall thickness >12 mm by echocardiogram or CMR (in the 
absence of alternative causes), or  
(3) Pyrophosphate (PYP) scintigraphy with myocardial uptake ≥ grade 2 (or 
heart/contralateral  chest ratio >1.5) using SPECT/CT scan if AL amyloidosis is 
excluded.  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 28 - 4) Able to undergo two  PET/CT scans as part of the study, including ability to lie supine for up 
to 1 hour. 
5) For w omen  of childbearing potential: agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per 
year during the treatment period and for at least 90 days after the last dose of 124I-AT-01.  
a) A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state ( ≥12 months of amenorrhea with no identified cause other than 
menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. 
b) Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices , and  copper intrauterine 
devices.  
c) Contraception methods that do not result in a failure rate of <1% per year such as cap, diaphragm, or sponge with spermicide, or male or female condom with or without spermicide, are not acceptable.  
d) The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.  
6) For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm, as defined below: 
a) With female partners of childbearing potential, men must remain abstinent or use a 
condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 120 days (a spermatogenesis 
cycle) after the last dose of study intervention. Men must refrain from donating sperm during this same time period. 
5.2 Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply: 
1) Is pregnant or breast-feeding. 
2) Is mentally or legally incapacitated, has significant emotional problems at the time of the 
study, or has a history of psychosis. 
3) Has received in the last 6 months or are currently receiving treatment with anti -amyloid 
monoclonal antibody therapy ( i.e., CAEL 101, NEOD001, PRX-004, or NI006) or are 
expected to begin treatment prior to completing this  study. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 29 - 4) Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 
days of Day 1 (first administration of 124I-AT-01). 
5) Has a significant co -morbidity (e.g., E COG score of 3 or greater), N YHA Class IV heart 
failure, uncontrolled infection, or other ongoing serious illness. 
6) Has a known allergy to potassium iodine treatment.  
7) Has end -stage renal disease and is receiving hemodialysis or peritoneal dialysis.  
8) Has severe claustrophobia that would prevent completion of the PET/CT imaging protocol. 
9) Has received an investigational agent within five  half-lives of the agent or 30 days, 
whichever is longer, prior to Screening.  
10) Has any illness tha t, in the opinion of the Investigator, might confound the results of the 
study or pose additional risk to the subject. 
5.3 Lifestyle Considerations  
Specific lifestyle considerations are not required.  
5.4 Screen Failures 
Subjects that fail screening will be record ed as screen failures in the source documentation.  
Subjects that terminate the study early may be replaced, as described in Section 5.5. 
5.5 Subject  Replacement  
Subjects that are withdrawn (except for an AE ) or are lost to follow-up during the study may be 
replaced to ensure an appropriate number of subjects complete the study. The decision to replace 
a subject will be made in agreement between the Sponsor and Investigator. Subjects who do not receive a second dose of 
124I-AT-01 or have a PET/CT scan following the second dose of 
124I-AT-01 will be replaced.  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 30 - 6.0 STUDY INTERVENTION(S) AND CONCOMITANT THERAPY  
6.1 Study Intervention(s)  
The s tudy intervention is described in Table 2. For complete information regarding the 
administration of study intervention, refer to the Study Manual .  
Table 2: Protocol AT01-001: Study Intervention 
Arm Name  124I-AT-01 
Intervention Name  124I-AT-01 
Type  Radiopharmaceutical  
Dosage Form  Solution for Injection  
Unit Dose Strength(s)  0.004 -0.037 GBq (0.1 -1 mCi)/mL ; NMT 2 mg AT -01 
Dosage Level(s)  1 mCi ( ± 10%) 124I-AT-01 
Half-life is 4.2 days. Calculate the correct dosage from date and time 
of calibration.  
Route of Administration  IV infusi on (2-5 minutes) or slow IV bolus at 1 mL/5 seconds . 
Additional details are provided in the Pharmacy Manual.  
Use Experimental  
IMP or NIMP  IMP 
Sourcing  124I-AT-01 will be manufactured for each subject  and will be supplied 
to the investigative site by the Sponsor.  
Storage  Store upright in a shielded container  at room temperature . The 
expiration time of 124I-AT-01 is 96 hours  after its  end of synthesis . 
Packaging and Labeling  Multidose 10 mL vial . 
Contains: [124I]p5+14, 1.3 -1.8 mg in phosphate -buffered saline ( PBS) 
for injection.  
>90% radiochemical purity (remainder iodide), >99% radionuclidic 
purity.  
The product is sterile and  non-pyrogenic. May be diluted with sodium 
chloride for injection (USP). 
DO NOT USE if cloudy or contains particulate matter.  
Handling  Aseptically withdraw and handle doses.  The empty syringe and IV 
administration sets shall  be disposed of in accordance with 
appropriate local radioactive waste management  guidance .  
Abbreviations: IMP = investigational medicinal product; IV = intravenous; NIMP = non- investigational medicinal 
product; NMT = no more than . 
 
6.2 Preparation/Handling/Storage/Accountability  
124I-AT-01 will be manufactured by 3 D Bioimaging, LLC ( Little Rock, AR ) and will be supplied 
to the investigative site in a multidose 10 mL vial . It will be delivered in a container with 
appropriate radioactive shielding. Any damage to the vial  should be reported immediately to both  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 31 - the Sponsor and 3D Imaging using the contact information provided in the P harmacy Manual. 
Store upright in a shielded container.  
Aseptically withdraw and handle doses. The h alf-life of 124I is 4.2 days. Calculate the correct 
dosage from date and time of calibration. The expiration time of 124I-AT-01 is 96 hours after its 
preparation. 
The empty syringe and IV administration sets will be disposed of in accordance with appropriate 
local radioactive waste management  guidance. 
The Investigator (or designee) will be responsible for keepi ng current and accurate records of the 
dose of 124I-AT-01 dispensed and its disposition. 
6.3 Measures to Minimize Bias 
Because this study is an exploratory, single  arm, open- label  human pharmacology study, 
measures to minimize bias are not  applicable. 
6.4 Study Intervention Compliance  
Only subject s enrolled in this study may receive treatment  with 124I-AT- 01. All study drug  
during the study will be administered by qualified clinical site staff. The date and time for each dose will be recorded in the CRFs. T he dat e of and reason for any deviations in protocol-
specified dosing will be documented in the case report forms. 
6.5 Dose Modifications/Interruptions and Retreatment Criteria  
Subjects may only receive the specified dose of 
124I-AT-01. Modifications of the dosage and 
retreatment are not allowed , except as provided in Section 7.1.1.  
6.6 Access to Study Intervention After End of Study  
Administration of 124I-AT-01 under this protocol will be completed at Visit 2  (Week 6  to 
Week  8). No further treatment with 124I-AT-01 will occur under this protocol, and 124I-AT-01 will 
not be made available to subjects by the Sponsor after completion of the study. 
6.7 Treatment of Overdose 
For this study, any dose of 124I-AT- 01 greater than 1.1 mCi or >2 mg AT-01 is considered 
overdose. There are no specific treatments for overdose. In the event of an accidental overdose, 
the Investigator should do the following: 
• Contact the Sponsor/Medical Monitor immediately;  
• In consultation with the Sponsor/Medical Monitor, determine, whether additional steps should be taken;  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 32 - • Closely monitor the subject  for any AE s or serious AEs  (SAEs) ; and 
• Document the quantity of the excess dose. 
 
6.8 Concomitant Medications and Procedures  
A concomitant medication is any drug or substance administered between signing the ICF and 
the EOS Visit. A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy) 
performed between obtaining informed consent and the EOS Visit that is not otherwise specified 
in the protocol.  
6.8.1 Allowed Concomitant Medications and Procedures 
There are no restrictions on concomitant medications, unless specified as prohibited (Section  6.8.2).  
6.8.2 Prohibited Concomitant Medications and Procedures  
Concurrent enrollment in any other drug, biologic, or device clinical study; or treatment with an unapproved investigational drug under development is prohibited. 
If a participant is scheduled for an electi ve procedure during the study, they should postpone the 
procedure until their participation in the study is complet e. 
Heparin or heparin analogs are prohibited within 7 days of a planned administration  of 
124I-AT-
01. Additional details are provided in Section 7.1.1.2. 
6.8.3 Rescue Medication or Supportive Therapy for Adverse Events  
Not applicable. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 33 - 7.0 DISCONTINUATION OF STUDY INTERVENTION AND/OR SUBJECT 
DISCONTINUATION OR WITHDRAWAL  
7.1 Discontinuation of Study Intervention 
All subject s are free to withdraw from participating in this study at any time for any reason, 
specified or unspecified, and without prejudice. No constraints will be placed on ordinary subject 
management.  
Subjects will be withdrawn  for any of the following reasons: 
• The subject withdraws consent. 
• The subject does not have amyloid deposits in the heart, liver, spleen or kidney on the 
Day 1 PET/CT scan, as described in Section 8.1.4. 
• The subject begins treatment with heparin or a heparin analog within 7 days of a planned administration  of 
124I-AT-01, as described in Section 7.1.1.2 . 
• The subject experiences an intolerable AE or serious AE  (SAE).  
• The subject enrolls into another clinical study in which an investigational treatment or 
approved therapy for investigational use is administered. 
• The subject becomes pregnant. Study treatment must be discontinued immediately. Report the pregnancy according to the instructions in Section 8.3.5. 
• The subject is unwilling or unable to comply with the protocol. 
• At the discretion of the Investigator or Sponsor.  
• Investigator decision that it is not in the best medical interest of the subject to continue participation in the investigation.  
• The Sponsor prematurely terminates the study. 
Prior to discontinuing a subject, every effort should be made to obtain as much follow- up data as 
possible. Withdrawn or discontinued subjects will undergo ET activities per the SoA (Section  1.3). Subject withdrawals will be  documented clearly on the source documents and 
applicable case report forms (CRFs). Subject withdrawals will be  documented clearly on the 
source documents and applicable CRFs .  
Discontinued subjects will be assessed for adverse events via a tele phone call 24 -48 hours after 
decision to discontinue. 
Notification of subject  withdrawals will be made to the Sponsor, or designee. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 34 - 7.1.1 Specific Stopping Criteria  
7.1.1.1 Infusion- related Reactions  
Infusion- related reactions ( IRRs ) can be any signs or symptoms experienced by subjects during 
the infusion of pharmacologic or biologic agents or any event occurring on the first day of the 
infusion ( Doessegger 2015). IRRs have been reported, among other terms, as anaphylaxis, 
anaphylactoid reactions, cytokine release syndrome, hypersensitivity reaction, etc. Symptoms suggestive of an IRR include but not limited to the following: tachypnea with respiratory distress, new onset rash or pruritus, chills, stridor, wheezing, swollen or itchy lips or tongue, onset of abdominal cramping, or hypotension. 
Treatment -emergent adverse events starting  on the day of 
124I-AT-01 admi nistration will be 
summarized to evaluate potential inf usion- related reactions.  
Subjects will be monitored for IRRs and managed as follows:  
• During administration of 124I-AT-01: if an IRR occurs during administration , the 
administration  will be immediately discontinued  and the subject will be treated for their 
symptoms  and discontinued from the study. Activities for Safety Follow-up 1 (1-3 days 
after the second  administration ) and Safety Follow -up 2/EOS (28 (± 3) days after the 
second  administration ) will be conducted, per the SoA ( Section  1.3).   
• After administration of 124I-AT-01: if an IRR occurs in a subject after completion of the 
administration , the subject will be treated for their symptoms, managed in accordance 
with stand ard of care, and the IRR will be recorded as an AE . If the symptoms respond 
promptly to minimal intervention (e.g., responds promptly to symptomatic treatment with 
antihistamines, acetaminophen, or nonsteroidal anti-inflammatory drugs ( NSAIDs) ) then, 
at the discretion of the Investigator, the subject may continue in the study. If the 
symptoms are prolonged (e.g., not rapidly responsive to symptomatic medication), require IV  fluids or treatments , or require hospitalization , the subject will be discontinued 
from the study. Activities for Safety Follow -up 1 (1-3 days after the second  
administration ) and Safety Follow-up 2/EOS (28 (± 3) days after the second  
administration ) will be conducted, per the SoA (
Section  1.3).  
7.1.1.2 Heparin  or Heparin Analogs  
Concomitant use of heparin or heparin analogs within 7 days of a planned administration  of 124I-
AT-01 is prohibited ( Section 6.8.2 ), as follows:  
• Subjects who have received heparin or a heparin analog within 7 days of Day 1 (first administration of 
124I-AT-01) are excluded from the study ( Section 5.2 ). 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 35 - • If a subject receives heparin or a heparin analog within 7 days of the planned Week 6 
administration  of 124I-AT-01 and PET/CT scan, they will be discontinued from the study 
(i.e., they will not receive a second administration  of 124I-AT-01 or undergo a second 
scan) and will undergo ET activities, as provided in the SoA ( Section  1.3) and as 
described in Section  4.1.5. 
If a subject be gins treatment with heparin or a heparin  analog after the Week 6 administration  of 
124I-AT-01 and PET/CT scan, they may  continue the study, as described in the SoA 
(Section  1.3).  
7.2 Missed Visits  
If a subject misses any of the scheduled visits, the visit  is considered missed and recorded as 
such in the source documents and CRFs.  
7.3 Lost to Follow- up 
Subjects who do not return for a scheduled visit (missed visit) and cannot be contacted, may be 
considered lost to follow- up. The site will attempt to contact the subject through a minimum of 
two telephone calls. If the subject still cannot be contacted, the site will send a certified letter to 
the last known address of the subject. If no contact is made by the subject, the site will consider 
the subject  lost to follow-up. All follow-up attempts will be documented and kept with the 
subject ’s source documentation, and the applicable CRFs will be completed . 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 36 - 8.0 STUDY ASSESSMENTS AND PROCEDURES  
8.1 124I-AT-01 Organ Uptake Assessments  
8.1.1 Medical History and Demographics 
Medical history includes clinically significant diseases, organ or stem cell transplants, and 
reproductive status. All prescription medications used by the subject regularly or within 30 days preceding Day -1 must be recorded. Prior or concurrent treatment regimens for systemic 
amyloidosis should be recorded. Demographic data will include age, sex , body mass index 
(BMI), amyloid subtype, time since diagnosis of syst emic amyloidosis, and ethnic origin (also 
referred to as self -reported race and ethnicity in some regions of the world). 
8.1.2 Biomarkers  
Biomarkers including NT -proBNP, brain natriuretic p eptide (BNP), serum free light chains (only 
subjects with AL amyloidosis), and UACR (only subjects with AL amyloidosis ) will be obtained 
at Screening  and Week 6 (Visit 2), as specified in the SoA ( Section  1.3). 
8.1.3 Administration of 
124I-AT-01 
124I-AT-01 will be administered while the subject is at the clinical site. 124I-AT-01 will be 
administered as described in Section 4.1.3. 
During 124I-AT-01 administra tion, monitor subject s for IRRs , as described in Section  7.1.1.  
8.1.4 124I-AT-01 PET/CT Imaging  
Planned time points for all PET/CT imaging  are provided in the SoA ( Section  1.3). Subjects will 
undergo a PET/CT scan 5 hours (± 30 minutes) after the start of administration  of 124I-AT-01 to 
quantify 124I-AT-01 uptake in organs. 124I-AT-01 whole- body scans  will be acquired using study-
designated PET/CT scanners (see Imaging M anual  for further information).  
Subjects without evidence of amyloid in at least one of the following organs on the Day 1 scan: 
heart, liver, kidneys, or spleen, will be discontinued from the study (i.e., not receive a second administration  of 
124I-AT-01 or undergo a second scan) and will undergo ET activities  provided 
in the SoA ( Section  1.3) and as described in Section 4.1.5. 
8.2 Safety Assessments  
Planned time points for all safety assessments are provided in the SoA ( Section  1.3). 
8.2.1 Vital Signs , Body Weight, and Height 
Planned time points for vital signs , body weight, and height are provided in the SoA 
(Section  1.3). Additional vital signs may be taken at any other times, if deemed necessary.  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 37 - Heart rate and blood pressure measurements will be performed with subjects in a supine position 
for at least 5 minutes, except when they are seated or semi -reclined because of study procedures 
and/or AEs (e.g., nausea, dizziness) , or if deemed necessary by the Investigator or designee. 
Blood pressure measurements should be measured on the same arm throughout the study. 
8.2.2 Clinical Laboratory Testing  
A list of clinical laboratory tests to be performed  is provided in Appendix 2.  
The clinical safety laboratory tests will be performed at a central  laboratory. Samples for 
complete blood count (CBC)  and chemistry should be obtained and analyzed based on central  lab 
requirements. Laboratory safety tests may be performed at various unscheduled time points, if 
deemed necessary by the Investigator or designee.  
8.2.3 Pregnancy Testing  
Subject samples for pregnancy testing will be acquired pre- administration  at the Screening  and 
Week 6  visit s in women of childbearing potential, as specified in the SoA ( Section 1.3 ). All 
women of childbearing potential (defi ned in Appendix 4) must have a negative pregnancy test 
prior to administration of 124I-AT-01 at the Day  1 and Week 6  visits  to participate in the study.  
Samples for serum pregnancy tests must be drawn within 7 days prior to  124I-AT-01 
administration for all women of childbearing potential. 
Prior to enrollment in the study, female subject s of childbearing potential and male subjects must 
be advised of the importance of avoiding pregnancy or partner pregnancy, respectively, during 
the trial, and the potential risks associated with an unintentional pregnancy. Contraceptive and barrier guidance and collection of pregnancy information is described in Appendix 4. 
8.2.4 Unscheduled Safety Visits  
Additional visits may be scheduled, as necessary, to ensure the safety and well -being of subject s. 
All additional exams should be fully documented in the source documents and on Unscheduled Visit CRFs, as appropriate. 
8.3 Adverse Events, Serious Adverse Events, and Other Safety Reporting  
The definitions of AEs and SAEs ; the methods of recording, evaluating, and assessing causality 
of AE s and SAE s; and the procedures for completing and transmitting SAE reports are provided 
in Appendix 3.  
Adverse events will be graded for seriousness, severity, and relationship to study drug treatment. After obtaining informed consent, each subject must be given the names and telephone numbers 
of study site staff for reporting AEs and medical emergencies. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 38 - 8.3.1 Time Period and Frequency for Collecting AE and SAE Information 
All AEs  and SAEs will be recorded  from the time of informed consent until the final EOS 
telephone follow-up (~Week 10).  
Throughout the study, every effort must be made to remain alert to possible AEs. If an AE 
occurs, the first concern should be for the safety of the subject . If necessary, appropriate medical 
intervention should be provided. 
8.3.2 Method of Detecting AEs and SAE s 
Adverse events may be spontaneously reported by the subject , obtained through non-leading 
questioning, or noted during examination of a subject . 
When recording an AE, a diagnosis is always preferable; however, in the absence of a diagnosis, 
the Investiga tor should record each sign and symptom as an individual AE.  
Medical or surgical procedures (e.g., cardiac ablation) should not be recorded as AEs. Rather, the condition for which the procedure was performed should be recorded. 
Adverse events will be reco rded from the time informed consent ( Section  10.1.3) is obtained 
through the end of the study. The data will be recorded on the appropriate CRF, regardless of 
whether they are thought to be associated with the study or treatment with study drug. 
Investigators are not obligated to actively seek SAE information from subjects that complete the study but are encouraged to notify the Sponsor or designee of any SAE occurring at any time after a subject  has discontinued or completed the study that they judge may be reasonably related 
to treatment with study drug or study participation. 
8.3.3 Follow- up of AEs and SAEs  
All related SAEs must be followed until resolution, until the condition stabilizes, until the event 
is otherwise explained, or the subject  is lost to follow -up. The Investigator is responsible for  
ensuring that follow -up includes any supplemental investigations as may be indicated to 
elucidate as completely as practical the nature and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, histopathological examinations, relevant hospital records (i.e., discharge summary), or consultation with other health care professionals. The Investigator must ensure that all subject identifiers are redacted from supportive 
documentation prior to submission. 
The Sponsor or designee may request that the Investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations. If a subject  dies during participation in the study 
or during a recognized follow-up period, the Sponsor or designee should be provided with a copy of any postmortem findings, including histopathology. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 39 - New or updated information obtained during SAE follow-up should be recorded in the 
original/existing form(s); updates should be made to the relevant data in the EDC. If EDC is not 
available, t hen new or updated information should be recorded on a new paper SAE form ; the 
original or prior paper SAE forms must not be re-used or altered. By signing the SAE form, the Investigator or designee attests to the accuracy and completeness of the data and that he/she has reviewed the report being submitted  and approve s it. If a paper form is used, the same 
information is to  be captured  in the EDC when EDC becomes available.  
8.3.4 Regulatory Reporting Requirements for SAEs 
Any SAE experienced by the subject  between the time of the signing of the  ICF and up to the 
EOS  telephone call (approximately Week 10) must  be recorded on an SAE form, regardless of 
the severity of the event or its relationship to treatment with study drug. O nce the Investigator 
determines that the event meets the protocol definition of an SAE , the SAE must be reported to 
the Sponsor, or designee, within 24 hours.  
Prompt notification of a n SAE by the Investigator to the Sponsor is essential to meet the legal 
obligations and ethical responsibilities regarding the safety of subjects and the safety of a study 
intervention under clinical investigation. Reporting of a SAE requires the following: 
• Completion  of the SAE Report F orm details  in the EDC , or if  the EDC is not available,  
transmission of the paper SAE Report Form to the Sponsor or designee, via email  as 
noted in the Study M anual . The SAE event  is to be reported within 24 hours of the 
Investigator’s knowledge of the event. If paper submission is used, the same  information 
is to be entered into the EDC when EDC becomes available.   
• Reporting of additional, follow-up information for previously reported SAEs should 
follow the same reporting timeframe and procedures as initial reports.  New or updated 
information should be made to the relevant data in the EDC. If EDC is not available , new 
or updated information should be recorded on a new paper SAE form; the original or prior paper SAE forms must not be re- used or altered .  
• Accompanying documentation, such as laboratory data, concomitant medication records, hospital records etc., should be redacted and transmitted to the Sponsor or designee as 
outlined in the Study Manual. In addition, the corresponding AE in the AE CRF (as applicable) should be updated to ensure all data points documented in the AE CRF are aligned with the matching data points on the SAE Report Form. 
The Sponsor has a legal responsibility to notify health authorities about the safety of a study intervention under clinical investigation. The Sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the local regulatory authority, Institutional 
Review Boards (IRB)/Independent Ethics Committees (IEC) , and Investigator s. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 40 - An Investigator who receives an Investigato r Safety R eport describing a n SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file 
it along with the  IB and will notify the IRB/IEC, as appropriate according to local requirements. 
Investiga tor Safety R eports must be prepared for suspected unexpected serious adverse reactions 
(SUSAR) according to local regulatory requirements and Sponsor policy and forwarded to 
Investigator s as necessary.  
8.3.5 Pregnancy  
The Investigator must report a pregnancy occurring in a female subject  to the Sponsor or 
designee within 24 hours of the study site staff becoming aware of the pregnancy. In addition, if a female subject  becomes pregnant within 12 weeks after last dose of study drug, the pregnancy 
must also be reported within 24 hours of the study site becoming aware of the pregnancy. The Investigator or study site staff must also follow the pregnancy until the outcome is known and submit the outcome as follow-up within 24 hours of notification of outcome. Follow-up Pregnancy Forms may be submitted as required as additional information is obtained. Although 
pregnancy occurring in a clinical study is not considered to be an AE or SAE, any pregnancy complication or elective te rmination of a pregnancy, for medical reasons, will be recorded as an 
AE or SAE and followed as such. Pregnancies in partners of male study subject s will similarly 
be monitored for the full duration of the pregnancy and/or followed through a definitive out come 
(i.e., birth, or spontaneous or elective abortion). Pregnancy reporting must be submitted via email as noted in the Study Manual. 
8.3.6 Death Events  
Death is an outcome of an event. The event that resulted in death should be recorded on the appropriate CRF. All causes of death must be reported as SAEs within 24 hours of the site becoming aware of the event. The Investigator should make every effort to obtain and send death certificates and autopsy reports to the Sponsor or designee. If cause of death is not available 
within the 24 -hour reporting period, “death” must be reported as the SAE term to meet timelines , 
and the cause of death must be actively queried and submitted as a follow-up report. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 41 - 9.0 STATISTICAL CONSIDER ATIONS  
9.1 Study  Hypothes is 
Not applicable. 
9.2 Definition of Enrollment 
“Enrolled” means a subject , or their legally authorized  representative, has provided agreement to 
participate in this clinical study following completion of the screening and informed consent 
processes . Potential subject s who are screened for the purpose of determining eligibility for the 
study, but who do not participate in the study, are considered screening failures and are not 
considered enrolled.  
9.3 Sample Size Determination  
A formal sample size calculation is not provided for this study. The sample size of up to 
20 subject s was estimated based on systematic literature review  analysis sets. 
9.4 Analysis Sets  
Safety analyses will be performed on the All -enrolled Population, consisting  of all subjects who 
undergo at least one PET/CT scan  or receive any amount of 124I-AT-01.  
Analyses of repeatability will be performed on the Image Evaluable Population, consisting of all subjects who undergo PET/CT scans on both Day 1 and 6 to 8 weeks after Day 1 and who have evaluable images at  both time points. 
9.5 Statistical Analyses  
The study statistical analysis plan ( SAP) will specify the statistical methodology and reporting 
for all aspects of the planned analyses. Additional unplanned analyses may be required. All  
unplanned analyses will be clearly identified in the clinical study report.  
9.5.1 General Considerations 
This is an open -label, single arm study. In general, for continuous variables, the mean, standard 
deviation (SD), median, and range will be presented. Categorical variables will be summarized by frequency counts and percentages. 
Subject disposition will be summarized for all subjects who signed the  ICF and will include the 
number of subject s who received study treatment and the number and percentage of subject s who 
completed or prematurely discontinued the study, classified by reasons for premature 
discontinuation. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 42 - Discontinuations   
The reason for study discontinuation and the number of days post-study drug treatment on which 
the subject  discontinued will be summarized. 
Protocol Deviations 
Protocol deviations will be provided in a listing with reasons for the deviation and the date of 
occurrence. Any exclusion of subject s from exploratory analysis populations, and how these 
exclusions impact data analysis, will be addressed in the clinical study report.  
Missing  Data  
There will be no imputation for missing safety or whole blood radioactivity data.  
9.5.2 Primary Endpoint(s)  
The primary objective of this study is to e valuate the repeatability of organ -specific quantitation 
of radiotracer uptake following PET/CT imaging of AT-01 in subjects with AL or ATTR 
systemic amyloidosis. The corresponding primary endpoint is :  
• Repeatability coefficient (Bland -Altman plots) and intraclass correlation coefficient 
(ICC) associated with the quantification of radioactivity associated with organ level 
124I-AT-01 uptake measurements. 
The signal to noise ratio ( SNR) and contrast to noise ratio (CNR) will be plotted against 
standardized uptake value (SUV) based metrics. Repeatability will be assessed using Bland -
Altman plots. ICC and its associated 95% confidence interval will be presented. Quantitative organ uptake analyzed by an automated method wil l be summarized. Between -reader agreement 
in visual determination of AT-01 uptake will be evaluated by Cohen’s kappa. 
9.5.3 Secondary Endpoint(s)  
The secondary objective of this study is t o characterize the safety and tolerability of repeat doses 
of 
124I-AT-01 administered by IV infusion or slow IV bolus. The corresponding secondary 
endpoints are as follows: 
• Incidence of treatment -emergent AEs from Day 1 to EOS . AEs will be graded using 
Common Terminology Criteria for Adverse Events ( NCI CTCAE ) version  5. 
• Change from Baseline in clinical laboratory values at Visits 2 and Safety Follow-up 1 ( 1-3 
days after the second administration of 124I-AT-01). Clinical laboratory tests are described in 
Section  10.2  and include hematology and serum chemistry.  
• Change from Baseline in vital signs. 
• Change from Baseline in ADA. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 43 - Exploratory analyses may be performed to examine the relationship between images and 
biomarkers including, but not limited to, NT- proBNP, free li ght chains (AL subjects only), and 
UACR (AL subjects only). 
9.5.4 Safety Analy sis 
Safety will be assessed through reported adverse events (graded using NCI CTCAE version 5) 
and changes in laboratory parameters. 
Adverse Events  
All adverse events occurring during the study will be recorded and classified based on Medical 
Dictionary for Regulatory Activities (MedDRA) terminology. Only treatment- emergent adverse 
events (TEAEs), which are adverse events that occur after the start of study drug , will be 
summarized.  
The number and percentage of subject s experiencing TEAEs and SAEs will be tabulated for the 
safety population by system organ class (SOC) and preferred term (PT). TEAEs and SAEs will 
be tabulated by severity and relationship to study medication. Each subject will be counted only once within a SOC or a PT by using the AE  with the highest severity or greatest relationship, 
respectively, within each category.  
TEAEs  or SAE s leading to early discontinuation will be summarized as described above.  
Treatment -emergent adverse events starting on the day of dosing at each dosing visit will be 
summarized by SOC and PT to evaluate potential infusion- related reactions.   
Listings for all reported adverse events, including SAEs, will be provided. In additi on, separate 
listing for SAEs, AEs leading to premature withdrawal from the study, and all deaths will be generated. 
Vital signs will include blood pressure (mmHg) and heart rate (beats per minute ). Vital signs will 
be summarized at Baseline and for each study visit when vital signs were obtained. Changes 
from Baseline in vital sign measurements will also be summarized. Baseline is defined as the last vital signs obtained prior to the initiation of study drug.  
Clinical Laboratory  Analys es 
Baseline for clinical chemistry parameters is defined as the most recent  laboratory measure ment  
obtained prior to the initiation of study drug. Clinical laboratory parameters from the tests 
itemized  in Section  10.2 , will be summarized as both absolute value and change from Baseline 
for each visit per the SoA ( Section 1.3).   
Laboratory parameters with quantitative abnormalities will be listed as ‘ flagged’ based on the 
Sponsor’s i ntern al guidelines. Flagged laboratory parameters  will be presented by incidence and 
frequency. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 44 - Clinical safety laboratory tests performed during the study will be analyzed by a  central  clinical 
laboratory. 
9.6 Interim Analyses  
Not applicable.  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 45 - 10.0 APPENDICES WITH SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
Appendix 2:  Clinical Laboratory Tests  
Appendix 3:  AEs and SAEs: Definitions and Procedures for Recording, Evaluating, Follow-up, 
and Reporting 
Appendix 4: Contraceptive and Barrier Guidance  
Appendix 5:  Protocol Amendment History  
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 46 - 10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1 Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• 21CFR Parts 50, 54, 56 and 312; 
• Applicable ICH Good Clinical Practice (GCP) Guidelines;  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS); and  
• Applicable local laws and regulations. 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and 
approved by the IRB/IEC before the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subject s.  
The Investigator is responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC at least annually, in accordance with the requirements, policies, and procedures established by the IRB/IEC ; 
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures ; and  
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, and all other applicable local regulations. 
10.1.2 Financial Disclosure  
Investigator s must  provide financial disclosure information to allow the Sponsor to submit 
complete and accurate certification or disclosure statements to the appropriate regulatory authorities. In addition, Investigators must provide to the Sponsor a commitment to promptly update this information if any relevant changes occur during the investigation and for 1 year following the completion of the study. 
Neither the Sponsor nor their Contract or Clinical Research Organization  (CRO) partn er is 
financially responsible for additional testing or treatment of any medical condition that may be 
detected during the screening process. In addition, in the absence of specific arrangements, neither the Sponsor nor their CRO are financially responsibl e for further treatment of the 
subject ’s disease. 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 47 - 10.1.3 Informed Consent  
A signed and dated IRB approved ICF will be obtained prior to any protocol- specified screening 
procedures being performed. Each subject will be provided with oral and written information 
describing the nature, purpose, and duration of the study; participation/termination conditions ; 
and risks and benefits. The subject will also sign and date an authorization form required under the Health Insurance Portability and Accountability Act (HIPPA),  if applicable, that authorizes 
the use and disclosure of the subject’s protected health information. The original signed ICF will be retained in the subject records, and a copy will be provided to the subject.  
Subjects unable to sign the ICF may participate in the study if a legal representative or witness 
provides the consent (in accordance with ICH -GCP and local regulations) and the subject 
confirms his/her interest in study participation. The subject will be informed that they can freely withdraw consent and stop participation in the study at any time with no prejudice post-study care.  
Subjects who are re- screened are required to sign a new ICF if it has been more than 30 days 
from the initial consent date.  
10.1.4 Data Protection 
Subjects will be sequentially assigned a study number at Screening that will be used throughout the study. All  subject  records or datasets that are transferred to the Sponsor will contain the 
identifier only; subject  names or other identifiable  information will n ot be transferred.  
The subject must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the subject  during the informed consent process ( Section 10.1.3).   
Subject medical information obtained by this study is confidential, and disclosure to third parties other than those noted below is prohibited. All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain subject  confidentiality. All 
records will be kept in a secure storage area with limited access. Upon the subject’s permission, medical information may be given to his or her personal physician or other appropriate medical personnel responsible for his or her welfare.  
The subject must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by health authority inspectors.  
All information provided by the Sponsor, verbally and in writing, is confidential. The Investigator agrees not to disclose any such information without prior written permission of the Sponsor. This document may be disclosed to study personnel under the Investigator’s supervision and to the IRB under the condition that they also agree to maintain its confidentiality. Any supplemental information (e.g., protocol amendment) that may be added to 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 48 - this document is confidential and must also be handled accordingly. The information obtained 
from the Sponsor may be disclosed to obtain informed consent from subject s who wish to 
participate in the study. 
Study documents provided by the Sponsor (protocols, IB, etc.) will be stored appropriately to 
ensure their confidentiality.  
The Investigator and all employees and co -workers involved with this study may not disclose or 
use for any purpose other than performance of the study any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the Sponsor or its designee must be obtained for the disclosure of any said confidential information to other parties. 
10.1.5 Data Quality Assurance 
All subject data relating to the study will be recorded on printed or eCRF unless transmitted to 
the Sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the eCRF.  
The Investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
Monitoring details describing strategy (e.g., risk- based i nitiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote,  or on-site monitoring) are provided in the Monitoring Plan. 
The Sponsor or designee is responsible for the data management of this study including quality checking of the data. 
The Sponsor assumes accountability for actions delegated to other individuals (e.g., CROs). Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the Investigator for 10 years after study completion unless local regulations or institutional policies require a longer retention perio d. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
10.1.6 Source Documents  
All medical information obtaine d at each study visit must be recorded in the subject ’s record 
(source documentation) in real time as it is collected. Source documentation consists of original 
subject documents, as well as data and records with information relevant to the subject  and 
his/her participation in the study.  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 49 - Source documents consist of, but are not limited to, subject hospital charts, clinic notes, subject 
medical records, original test results, laboratory data, worksheets, drug accountability records, consent forms, t elephone records, etc. Source documents must be available for review and 
inspection during on-site monitoring of the study by the Sponsor, their designees, the IRB, and/or appropriate regulatory authorities.  
Subject- completed forms are also considered sour ce data. Only subject s are to record 
information in subject diaries and questionnaires, if used. In no instance should an Investigator or study site personnel record any data or make changes to subject -completed forms. The 
Investigator or designee should r eview subject -completed forms during study visits. If an entry is 
found to be illegible or a mistake is found (e.g., incorrect year was recorded), the subject  may be 
instructed to edit the entry  
10.1.7 Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
subjects.  
Study/Site Termination  Due to Adverse Events 
Study stopping criteria due to adverse events are provided in Section 7.1.1. 
Study/Site Termination Due to Other Reasons  
The Sponsor or designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study site closure visit has been performed.  
The Investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to: 
For study termination: 
• Discontinuation of further study intervention development. 
For site termination : 
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor's procedures, or GCP guidelines; and/or 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 50 - Inadequate or no recruitment (evaluated after a reasonable amount of time) of subject s by the 
Investigator. If  the study is prematurely terminated or suspended, the Sponsor shall promptly 
inform the Investigator s, the IECs/IRBs, the regulatory authorities,  and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by the 
applicable regulatory requirements. The Investigator shall promptly inform the subject and should assure appropriate subject thera py and/or follow -up 
10.1.8 Publication Policy  
• All study data generated from this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented at scientific meetings by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, such that confidential or proprietary information is not disclosed. 
• Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee, for comment. Such comments shall aim to ensure the scientific integrity of the proposed publications and/or presentations and ensure that the data and material refe rring to Attralus, Inc products and activities receive 
fair, accurate, and reasonable presentation.  
• The Sponsor will comply with the requirements for publication of study results.  
• Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.  
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 51 - 10.2 Appendix 2: Clinical Laboratory Tests  
Laboratory 
Tests   Parameters  
Hematology  Complete blood count (CBC) with differential   WBC  differential : 
• Bands/stabs  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  White blood cell (WBC)  count 
Red blood cell (RBC) count  
Hemoglobin (Hgb)  
Hematocrit  (Hct)  
Platelet count (Plt)  
Serum  
Chemistry  Sodium (Na)  Creatinine (Cr)  Alanine aminotransferase 
(ALT, SGPT)  
Potassium (K)  Uric acid  Aspartate aminotransferase 
(AST, SGOT)  
Chloride (Cl)  Albumin  Calcium (Ca)  
Bicarbonate (HCO 3)/CO 2 Total protein  Phosphate (PO 4) 
Glucose  Total bilirubin  Lactate dehydrogenase (LDH ) 
Blood urea nitrogen (BUN)  Alkaline phosphatase   
Biomarker 
Assays  N-terminal prohormone of brain natriuretic 
peptide (NT -proBNP)  Serum free light chain1 
Brain natriuretic peptide (BNP)  Urine albumin creatinine ratio (UACR )1 
Pregnancy 
Testing  Highly sensitive serum human chorionic gonadotropin (hCG) pregnancy test (as needed for 
women of childbearing potential)2 
1. Subjects with AL systemic amyloidosis only.  
2. Serum pregnancy and laboratory tests must be drawn within 7 days prior to 124I-AT-01 administration in all 
WOCBP. The results of the pregnancy test must be available and be negative prior to 124I-AT-01 
administration in all WOCBP.  
 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 52 - T 
10.3 Appendix 3: AEs  and SAEs : Definitions and Procedures for Recording, Evaluating, 
Follow- up, and Reporting  
10.3.1 Definition of AE 
AE Definition  
• An AE is any untoward medical occurrence in a clinical study subject , temporally associated with the use of 
study intervention, whether or not considered related to the study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.  
 
Definition of Unsolicited and Solicited AE  
• An unsolicited AE is an AE that was not solicited using a Subject  Diary and that is communicated by a 
subject  or subject ’s parent(s)/  legally authorized representative ( LAR ) who has signed the informed consent. 
Unsolicited AEs include serious and non- serious AEs.  
• Potential unsolici ted AEs may be medically attended (i.e., symptoms or illnesses requiring a hospitalization , 
or emergency room visit, or visit to/by a health care provider). The subjects or subject’s parent(s)/LAR will 
be instructed to contact the site as soon as possible to report medically attended event(s), as well as any 
events that, though not medically attended, are of subjec t or parental/LAR’s concern. Detailed information 
about reported unsolicited AEs will be collected by qualified site personnel and documented in the subject ’s 
records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by the subject or subject’s 
parent(s)/LAR(s) will be collected during interview with the  subject or subject ’s parent(s)/LAR( s) and by 
review of available medical records at the next visit.  
• Solicited AEs are predefined local (at the infusion  site) and systemic events for which the subject is 
specifically questioned, and which are noted by the subject in their diary.  
 
Events Meet ing the AE Definition  
• Any abnormal laboratory test results (h ematology , clinical chemistry, or urinalysis) or other safety 
assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from 
Baseline, considered clinically significant in the medical and scientific judgment of the Investigator  (i.e., not 
related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in frequency 
and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention - intervention interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.  
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 53 - Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the Investigator  to be more severe than expected for 
the subject ’s condition.  
• The disease/disord er being studied or expected progression, signs, or symptoms of the disease/disorder being 
studied, unless more severe than expected for the subject’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the  procedure is 
the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a 
hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the start 
of the study that do not worsen.  
 10.3.2 Definition of SAE  
An SAE is defined as any serious AE that, at any dose:  
• Results in death  
• Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject  was at risk of death 
at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
- In general, hospitalization signifies that the subject  has been admitted (usually involving at least an 
overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have 
been appropriate in the physician’s office or out patient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE 
should be considered serious.  
- Hospitalization for elective treatment of a pre -existing condition that did not worsen from Baseline is 
not considered an AE.  
• Results in persistent or significant disability/incapacity  
- The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
- This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trau ma (e.g., sprained 
ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption.  
• Is a congenital anomaly/birth defect  
• Other situations:  
- Medical or scientific judgment should be exercised by the Investigator  in deciding whether SAE 
reporting is appropriate in other situations such as significant medical events that may jeopardize the subject  or may require medical or surgical intervention to prevent one of the other outcomes listed in the 
above definitio n. These events should usually be considered serious.  
- Examples of such events include invasive or malignant cancers, intensive treatment for allergic bronchospasm, blood dyscrasias, convulsions , or development of intervention dependency or 
intervention abuse.
 
   
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 54 - 10.3.3 Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all documentation (e.g., 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event.  
• The Investigator  will then record all relevant AE/SAE information.  
• It is not acceptable for the Investigator  to send photocopies  of the subject ’s medical records to the Sponsor or 
designee in lieu of completion of SAE/AE required form.  
• There may be instances when copies of medical records for certain cases are requested by the Sponsor or 
designee. In this case, all subject  identifi ers, with the exception of the subject number, will be redacted on the 
copies of the medical records before submission to the Sponsor or designee.  
• The Investigator  will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be 
documented as the AE/SAE.  
Assessment of Intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported during the study and ass ign 
it to one of the following categories:   
• Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with 
everyday activities.  
• Moderate: An event that causes sufficient discomfort to interfere with normal everyday activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least one  of the predefined outcomes as described in the 
definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study intervention and each occurrence of 
each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a re lationship cannot be ruled out.  
• The Investigator  will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.  
• The Investigator  will also consult the I B and/or Product Information, for marketed products, in his/her 
assessment. 
• For each AE/SAE, the Investigator  must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred,  and the Investigator  has minimal information to 
include in the initial report to Attralus,  Inc. However, it is very important that the Investigator  always make 
an assessment of causality for every event before the initial transmission of the SAE data to Attralus, Inc . 
• The Investigator  may change his/her opinion of causality in light of follow -up information and send an SAE 
follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 55 -  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluations as medically indicated or as requested by Attralus, Inc to elucidate the nature and/or causality of 
the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
• If a subject  dies during participation in the study or during a recognized follow -up period, the Investigator  
will provide Attralus, Inc with a copy of any postmortem findings including histopathology.  
• New or updated information will be recorded in the originally submitted documents.  
• The Investigator  will submit any updated SAE data to Attralus, Inc within 24 hours of receipt of the 
information.  
 10.3.4 Reporting of SAEs  
SAE Reporting to Attralus, Inc . via the Electronic Data Collection (EDC) System  
• The primary mechanism for reporting an SAE to Attralus, Inc . will be the EDC  system . 
• If the EDC  system is unavailable, then the site will use the paper SAE data collection tool (see next section) 
to report the event within 24 hours.  
• The site will enter the SAE data into the EDC  system as soon as it becomes available.  
• After the study is completed at a given site, the EDC system  will be taken off- line to prevent the entry of new 
data or changes to existing data.  
• If a site receives a report of a new SAE from a study subject  or receives updated data on a previously 
reported SAE after the EDC system  has b een taken off -line, then the site can report this information as noted 
in the Study Manual . 
• Contacts for SAE reporting can be found in the Study Manual.  
 
SAE Reporting to Attralus, Inc. via Paper Data Collection Tool  
• It is the responsibility of the Investigator to report  SAEs to the Sponsor within 24 hours of awareness of the 
event or safety information, whether initial or follow -up. Do not delay in the reporting of suspected SAE in 
order to obtain additional information . Any additional information, if collected, can be reported to the 
Sponsor as a follow -up to the initial report . 
• In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.  
• Initial notification via telephone does not replace the need for the Investigator  to complete and sign the 
SAE data collection tool within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the Study Manual. 
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 56 - 10.4 Appendix 4: Contraceptive and Barrier Guidance  
10.4.1 Definitions  
Wom en of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear (e.g.,  amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP: 
• Premenarchal ; or 
• Premenopausal female with one of the following: - Documented hysterectomy  
- Documented bilateral salpingectomy 
- Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the above, 
(e.g., Müllerian agenesis, androgen insensitivity), Investigator discretion should be applied to determining study entry.  
Note: Documentation can come from the site personnel’s: review of the subject ’s medical 
records, medical examination, or medical history interview.  
Postmenopausal F emale 
A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.  
A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required. The Screening V isit FSH will be processed 
using the chemistry tube and the Day 1 FSH wi ll need to be collected separately and sent to the 
central lab for analysis.  A pregnancy test is required until both FSH measurements have been 
collected and results have been received that verify the post menopausal state of the female 
subject. 
Females on HRT and whose menopausal status is in doubt will be required to use one of the non-
estrogen hormonal highly effective contraception methods if they wish to continue their HRT 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 57 - during the study. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status before study enrollment. 
10.4.2 Contraception Guidance  
For Women of Childbearing Potential 
Agreement to remain as abstinent (refrain from heterosexual intercourse) or use contraceptive 
methods that result in a failure rate of <1% per year during the treatment period and for at least 
90 days after the last dose of study intervention.  
a. A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state ( ≥12 months of amenorrhea with no identified c ause other than 
menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. 
b. Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices , and  copper intrauterine 
devices.  
c. Contraception methods that do not result in a failure rate of <1% per year such as cap, 
diaphragm, or sponge with spermicide, or male or female condom with or without spermicide, are not acceptable.  
The reliability of sexual abstinence should be evaluated in relation to the dur ation of the clinical 
trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. 
For Men:  
Agreement to r emain abstinent or use contraceptive measures and agreement to refrain from 
donating sperm, as defined below: 
a. With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together re sult in a failure rate of 
<1% per year during the treatment period and for at least 30 days plus 90 days (a spermatogenesis cycle) after the last dose of study intervention. Men must refrain from donating sperm during this same time period 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 58 - 10.4.3 Collection of Pregnancy Information  
Female S ubject s Who Become P regnant  
• The Investigator will collect pregnancy information on any female subject  who becomes 
pregnant while participating in this study. The initial information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a subject 's 
pregnancy.  
• The subject will be followed to determine the outc ome of the pregnancy. The Investigator 
will collect follow -up information on the subject  and the neonate and the information will be 
forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective term ination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or stillbirth (occurring at >22 weeks gestational age) is always considered to be an SAE and will be reported as s uch.  
• Any post-study pregnancy related SAE considered reasonably related to the study intervention by the Investigator will be reported to the Sponsor, as described in Section 8.3.5. While the Investigator is not obligated to actively seek this information in former study subjects, he or she may learn of an SAE through spontaneous reporting. 
• Any female subject who becomes pregnant while participating in the study will discontinue study intervention or be withdrawn from the study. 
Male S ubject s with P artners Who Become P regnant  
• The Investigator will attempt to collect pregnancy information on any male subject’s female partner who becomes pregnant while the male subject  is in this study. This applies only to 
male subject s who receive any study intervention. 
After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
  
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 59 - 10.5 Appendix 5 : Protocol Amendment History  
The amendment history for Protocol AT01-001 is provided in Table 3. 
Table 3: Protocol AT01-001: Amendment History  
Version  Version Date  Brief Description   
2.0 08 March  2022  Revisions from Version 1.1 include the following:  
• Addition of slow IV bolus at 1 mL/5 seconds  as a method of 
administration.  
• Updated clinical experience to reflect final results  from Study 
AMY1001.  
• Minor administrative and editorial revisions.  
1.1 07 October 2021  Revisions from Version 1.0 include the following:  
• Addition of heparin/heparin analogs as a prohibited concomitant 
medication within 7 days of infusion of 124I-AT-01. 
• Minor administrative and editorial revisions.  
1.0 27 September 2021  • Original protocol ; used for pre -submission activities. This version 
was not submitted to any health authorities  or IRBs/ECs, nor was it 
implemented . 
 
CONFIDENTIAL  Protocol  AT0 1-001, Version 2.0 
Attralus, Inc.  124I-AT-01 
 - 60 - 11.0 REFERENCES  
1. CIOMS. 2005. "Management of Safety Information From Clinical Trials." In Report of 
CIOMS Working Group VI . Geneva: Council for International Organizations of Medical 
Sciences (CIOMS).  
2. Doessegger LBanholzer ML. 2015. Clinical development methodology for infusion ‐
related reactions with monoclonal antibodies. Clinical & translational immunology, 4: e39. 
3. Dorbala S, Vangala D, Semer J , et al. 2014. Imaging cardiac amyloidosis: a pilot study 
using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging, 41: 1652-62. 
4. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN , et al. 2007. Diagnostic 
performance and prognostic value of extravascular retention of 123I- labeled serum 
amyloid P component in systemic amyloidosis. J Nucl Med, 48: 865-72. 
5. Meikle SR, Sossi V, Roncali E , et al. 2021. Quantitative PET in the 2020s: a roadmap. 
Physics in Medicine & Biology, 66: 06RM01. 
6. Milani P, Merlini G, and Palladini G. 2018. Novel Therapies in Light Chain Amyloidosis. Kidney Int Rep, 3: 530-41. 
7. Muchtar E, Dispenzieri A, Magen H , et al. 2021. Systemic amyloidosis from A (AA) to T 
(ATTR): a review. Journal of Internal Medicine, 289: 268-92. 
8. Palladini G, Milani P, and Merlini G. 2020. Management of AL amyloidosis in 2020. Hematology 2014, the American Society of Hematology Education Program Book, 2020: 363-71. 
9. Rapezzi C, Quarta CC, Guidalotti PL , et al. 2011. Role of (99m)Tc- DPD scinti graphy in 
diagnosis and prognosis of hereditary transthyretin- related cardiac amyloidosis. JACC 
Cardiovasc Imaging, 4: 659-70. 
10. Wall JS, Martin EB, Richey T , et al. 2015. Preclinical Validation of the Heparin- Reactive 
Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis. Molecules, 20: 7657-82. 
11. Wall JS, Martin EB, Endsley A , et al.  2021. First in Human Evaluation and Dosimetry 
Calculations for Peptide 124I-p5+ 14—a Novel Radiotracer for the Detection of Systemic 
Amyloidosis Using PET/CT Imaging. Molecular Imaging and Biology: 1- 10. 
12. Wechalekar AD, Gillmore JD, and Hawkins PN. 2016. Systemic amyloidosis. The Lancet, 387: 2641-54. 
 